University of Pennsylvania

ScholarlyCommons
Publicly Accessible Penn Dissertations
2017

Heterogeneity In Major Depression: Influence On Treatment
Outcomes And Processes-Outcome Relations
Lorenzo Lorenzo-Luaces
University of Pennsylvania, lorenzl@sas.upenn.edu

Follow this and additional works at: https://repository.upenn.edu/edissertations
Part of the Clinical Psychology Commons

Recommended Citation
Lorenzo-Luaces, Lorenzo, "Heterogeneity In Major Depression: Influence On Treatment Outcomes And
Processes-Outcome Relations" (2017). Publicly Accessible Penn Dissertations. 2445.
https://repository.upenn.edu/edissertations/2445

This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/2445
For more information, please contact repository@pobox.upenn.edu.

Heterogeneity In Major Depression: Influence On Treatment Outcomes And
Processes-Outcome Relations
Abstract
Some have proposed that all psychotherapies for depression, as well as for other common mental
disorders, are equally efficacious and that they all work through common processes, especially a
relationship with a therapist. One reason it may be difficult to discern differential efficacy among
treatments, as well as how they exert their effects, is that depression and other disorders are
heterogeneous in both presentation and prognosis. The studies presented in the dissertation aimed to
explore how heterogeneity in depression may moderate treatment effects and process-outcome relations.
In study 1, a prognostic index (PI) was developed and treatment differences along the PI were explored in
a sample of patients (N = 622) randomized to treatment as usual (TAU) or stepped care starting with brief
therapy (BT) or with cognitive-behavioral therapy (CBT). The PI comprised five variables: unemployment
status, depression severity, hostility, sleep problems, and lower positive emotionality, all of which
predicted a lower likelihood of recovery. For patients whose PI indicated a high likelihood of recovery
(73% of the sample), recovery rates were similarly high across the treatments. Among patients whose PI
indicated a lower likelihood of recovery, patients in the CBT condition experienced a substantially higher
recovery rate (65%) than patients in TAU (40%) or BT (44%). In study 2, variability in the predictive
relationship between the therapeutic alliance and depressive symptom change was explored in a sample
of patients receiving cognitive therapy (CT) for depression (N = 60). The alliance predicted outcome in the
subgroup of clients with 0–2 prior episodes (r = .52), but not in those with 3 or more prior episodes (r =
-.02). In study 3, these findings were replicated in an independent sample of patients receiving CBT for
depression, but they did not extend to patients in a psychodynamic therapy condition. Taken together,
these findings suggest that there may be identifiable subgroups of patients for whom factors common to
all treatments will promote symptom change. By contrast, complementary subgroups, such as those with
poorer prognoses or more recurrent histories of depression, may reveal differences in the efficacies of
treatments and their active mechanisms.

Degree Type
Dissertation

Degree Name
Doctor of Philosophy (PhD)

Graduate Group
Psychology

First Advisor
Robert J. DeRubeis

Subject Categories
Clinical Psychology

This dissertation is available at ScholarlyCommons: https://repository.upenn.edu/edissertations/2445

HETEROGENEITY IN MAJOR DEPRESSION: INFLUENCE ON TREATMENT
OUTCOMES AND PROCESSES-OUTCOME RELATIONS
Lorenzo Lorenzo-Luaces
A DISSERTATION
in
Psychology
Presented to the Faculties of the University of Pennsylvania
in
Partial Fulfillment of the Requirements for the
Degree of Doctor of Philosophy
2017

Supervisor of Dissertation

Graduate Group Chairperson

Dr. Robert J. DeRubeis

Dr. Sara Jaffee

Samuel H. Preston Term Professor in

Professor of Psychology

the Social Sciences

Dissertation Committee
Dr. Ayelet Meron Ruscio (Chair), Associate Professor of Psychology
Dr. Dianne Chambless, Professor of Psychology

ACKNOWLEDGMENTS
I would like to start this acknowledgment section, and thus this dissertation,
by doing something atypical but cool like thanking all the haters for giving me the
drive to keep going. Unfortunately, I cannot really do that and instead have to join
the cliché in being extremely grateful for being surrounded by great people who have
directly or indirectly contributed to the development of this dissertation. I would like
to thank, in no specific order, my graduate committee, my friends –at Penn and
otherwise— my family, and my advisor.
Ayelet and Dianne thank you for being members of my committee; you were
great complements to Rob’s mentoring. Ayelet, I think you are an amazing teacher;
the course I took with you stands out as one of the best classes I have ever taken. I
am very glad I chose you as the chair of my committee. Although, I only recall a
handful of times when we met individually, those times stand out to me because I
left your office with great clarity. Dianne, I learned a lot from you about research
methods, integrity, and thoroughness. I appreciate your commitment to the program
and its students. I am extremely grateful for the opportunity to come to Penn when I
was an undergraduate. That summer experience was instrumental in my
development as a researcher and I know it contributed substantially to my coming
here.
I am also grateful for my “old” and “new” friends. My old friends, Noelia,
Natalisse, Sebastian, and Laura, I am acknowledging you here, partially because if I
omitted you there be several fits coming my way but also because you guys root for
me and have been key people in my life. My peers at Penn have also been a great
source of support. Eliora, you are the #2 best person in the program, which is about
as good as it gets. Hana, I love you and I know you are going to do amazing things
for the field and I look forward to hearing about them when continue to be best
friends in the future. Rami, you are probably the reason I got through a difficult 3rd
year and you were an amazing supervisor. You are an even better friend and I’m
extremely grateful for having you in my life. Zach (or Zack), you were like a brother
to me and I usually have fun with you whether riding a tandem bike in Germany or
trolling random e-mail threads. Sarah, I am going to miss our lunches catching up on
the program. Same for Rachel and Lauren, my lil sibs! I hope I was helpful or least
amusing. Jack, I pass on the mantle of emotional labeling in the lab as well as the
presidency of the LGBTQIA group of the DeRubeis lab. Incidentally, this also gets you
the presidency of the Hispanic/Latino division of the lab. I know you will do great
with these things as with everything else. Collin, I am sorry I did not get to see most
of your journey through PhDdom but I expect you will be great. You have a talented
set of big brothers who are always there for you. My other classmates, Kelly, Gwen,
Caitlin, Angelica and everyone else who it now occurs to me probably will not read
this: good luck, I hope we keep in touch, and I think you are amazing.
I would also like to thank my Dutch colleagues, and probably also the country
of Holland because two-thirds of the data for my dissertation come from there Dutch.
Marcus, Ellen, Annemieke, Fionneke, Suzanne, Kim, Claudi, Fitz, and Lotte thanks for
the friendships and the collaborations. Ellen and Annemieke, thanks for making this
dissertation possible. Marcus, thanks for hosting me, although I’m sure I may have
lost some neurons in the process. Lotte (and more Menno), I have enjoyed our time
together, especially when you are fit. I keep hoping you move to the States but

ii

Maastricht is very lucky to have you, a fact I hope they realize. My primary concern
is whether you are gymming but I have so much affection for you that I am willing to
overlook that.
Finally, I almost have to thank my crazy, crazy family. I love you and admire
you all. You have taught me many things about grit, perseverance, and friendship.
Rob (Rick!), I am not even sure what, of the many things, to say. You have
taught me a great deal about many things, including writing. As I write this,
however, I cannot help but think this acknowledgment section would be better if it
had your input. This is not just me trying to be cute, this paragraph has probably
been the hardest part of the dissertation to write and, even as I go over it, it feels
incomplete. I am proud of the decisions I made leading up to graduate school and
choosing to work with you was both the best and easiest decision I have ever had to
make. As an undergraduate, I was fortunate enough to have amazing mentors and
even great bosses but my experience working with you in the summer internship
really changed my thinking and helped refine my research interests. If these past 56 years had only been about the research, graduate school still would have been a
very rewarding experience but you have been more than an advisor to me. I am
going to miss like crazy gymming, my emergency Diet Cokes, getting your advice,
and, most of all, you. Oftentimes, when I face difficult decisions, I think about what
you would do. I usually end up doing something different because we are different
people but you make my thinking better. The level of care and attention that you
devote to things, and to people, is something to admire. None of the amazing things
that have happened to me in the past five years – from publishing my research to
traveling internationally for the first time to meeting amazing new people – would
have been possible without you. Thank you so much buddy.

iii

ABSTRACT
HETEROGENEITY IN MAJOR DEPRESSION: INFLUENCE ON TREATMENT OUTCOMES
AND PROCESSES-OUTCOME RELATIONS
Lorenzo Lorenzo-Luaces
Robert J. DeRubeis
Some have proposed that all psychotherapies for depression, as well as for
other common mental disorders, are equally efficacious and that they all work
through common processes, especially a relationship with a therapist. One reason it
may be difficult to discern differential efficacy among treatments, as well as how
they exert their effects, is that depression and other disorders are heterogeneous in
both presentation and prognosis. The studies presented in the dissertation aimed to
explore how heterogeneity in depression may moderate treatment effects and
process-outcome relations. In study 1, a prognostic index (PI) was developed and
treatment differences along the PI were explored in a sample of patients (N = 622)
randomized to treatment as usual (TAU) or stepped care starting with brief therapy
(BT) or with cognitive-behavioral therapy (CBT). The PI comprised five variables:
unemployment status, depression severity, hostility, sleep problems, and lower
positive emotionality, all of which predicted a lower likelihood of recovery. For
patients whose PI indicated a high likelihood of recovery (73% of the sample),
recovery rates were similarly high across the treatments. Among patients whose PI
indicated a lower likelihood of recovery, patients in the CBT condition experienced a
substantially higher recovery rate (65%) than patients in TAU (40%) or BT (44%).
In study 2, variability in the predictive relationship between the therapeutic alliance
and depressive symptom change was explored in a sample of patients receiving
cognitive therapy (CT) for depression (N = 60). The alliance predicted outcome in
the subgroup of clients with 0–2 prior episodes (r = .52), but not in those with 3 or
more prior episodes (r = -.02). In study 3, these findings were replicated in an
independent sample of patients receiving CBT for depression, but they did not extend
to patients in a psychodynamic therapy condition. Taken together, these findings
suggest that there may be identifiable subgroups of patients for whom factors
common to all treatments will promote symptom change. By contrast,
complementary subgroups, such as those with poorer prognoses or more recurrent
histories of depression, may reveal differences in the efficacies of treatments and
their active mechanisms.

iv

TABLE OF CONTENTS
ACKNOWLEDGMENTS .................................................................................. II
ABSTRACT ................................................................................................... IV
LIST OF TABLES ........................................................................................ VII
LIST OF ILLUSTRATIONS .......................................................................... VIII
CHAPTER 1: A PROGNOSTIC INDEX AS A MODERATOR OF OUTCOMES IN THE
TREATMENT OF MOOD DISORDERS: COMBINING MULTIPLE VARIABLES TO
INFORM STEPPED CARE ASSIGNMENT .......................................................... 1
ABSTRACT .................................................................................................... 2
INTRODUCTION ............................................................................................ 4
METHODS .................................................................................................. 10
RESULTS .................................................................................................... 15
DISCUSSION .............................................................................................. 18
CHAPTER 2: CLIENT CHARACTERISTICS AS MODERATORS OF THE RELATION
BETWEEN THE THERAPEUTIC ALLIANCE AND OUTCOME IN COGNITIVE
THERAPY FOR DEPRESSION ....................................................................... 27
ABSTRACT .................................................................................................. 28
INTRODUCTION .......................................................................................... 29
METHOD .................................................................................................... 30
RESULTS .................................................................................................... 33
DISCUSSION .............................................................................................. 34
CHAPTER 3: MODERATION OF THE ALLIANCE-OUTCOME ASSOCIATION BY
PRIOR EPISODES: A DIFFERENTIAL EFFECT IN COGNITIVE-BEHAVIORAL VS.
PSYCHODYNAMIC THERAPY FOR DEPRESSION ........................................... 42
ABSTRACT .................................................................................................. 43
INTRODUCTION .......................................................................................... 44

v

METHODS .................................................................................................. 49
RESULTS .................................................................................................... 53
DISCUSSION .............................................................................................. 54
CHAPTER 4: GENERAL DISCUSSION ........................................................... 63
BIBLIOGRAPHY .......................................................................................... 73
APPENDIX .................................................................................................. 94

vi

LIST OF TABLES

CHAPTER 1
Table 1.1 Baseline demographic, personality, and clinical characteristics of subjects
randomized to treatment as usual (TAU), brief therapy (BT), or cognitivebehavioral therapy (CBT) ............................................................................. 23
Table 1.2 LASSO solution for predictor variables used in prognostic index (PI)
predicting recovery at follow-up and model estimates from logistic regression using
these variables ........................................................................................... 25
CHAPTER 2
Table 2.1: Characteristics of the sample and bivariate associations between client
baseline characteristics, WAI-O ratings and subsequent change ...................... 38
CHAPTER 3
Table 3.1: Baseline characteristics of 282 patients assigned to cognitive-behavioral
therapy (CBT) or short-term psychodynamic supportive psychotherapy (SPSP) for
depression) ................................................................................................ 61

vii

LIST OF ILLUSTRATIONS

CHAPTER 1
Figure 1.1 Recovery rates at follow-up between treatment as usual (TAU), and
stepped care starting with brief therapy (BT) or cognitive-behavioral therapy
(CBT)…………………………………………………………………………………………………………………………26
CHAPTER 2
Figure 2.1: Predicted association between therapeutic alliance and subsequent
symptom change across prior depressive episodes .......................................... 38
Figure 2.2: Observed relationship between early ratings of the therapeutic alliance
and subsequent change, by prior number of episodes ...................................... 41
CHAPTER 3
Figure 3.1. Association between the alliance and symptom change by treatments
and prior episodes ....................................................................................... 62

viii

CHAPTER 1: A PROGNOSTIC INDEX AS A MODERATOR OF OUTCOMES IN THE
TREATMENT OF MOOD DISORDERS: COMBINING MULTIPLE VARIABLES TO
INFORM STEPPED CARE ASSIGNMENT
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ABSTRACT
Prognostic indices (PIs) that combine more than one variable to predict subsequent
depression risk may help guide the selection of treatments that differ in intensity. We
demonstrate the development of a PI and show its promise in guiding treatment
decisions between treatment as usual (TAU), stepped care starting with a low
intensity treatment (brief therapy (BT)), or stepped care starting with a high
intensity treatment (cognitive-behavioral therapy (CBT)). We utilized data from
depressed patients (N = 622) who participated in a randomized comparison of TAU,
BT, and CBT in which no statistically significant differences in the primary measure of
outcome emerged between the three treatments. We developed a PI by predicting
depression risk at follow-up across the entire sample using a LASSO-style bootstrap
ranking variable selection procedure. We then examined between-treatment
differences in outcome as a function of the PI. Unemployment status, depression
severity, hostility, sleep problems, and lower positive emotionality at baseline
predicted a lower likelihood of recovery across treatments. The resulting PI
incorporating these variables produced a good classification accuracy (c = 0.73). The
PIs of 73% of the patients indicated a high likelihood of recovery from MDD within
the 2-year study period. Of these, 81% recovered irrespective of condition. Among
the 27% of the sample with the lowest PIs, patients in the CBT condition experienced
a higher recovery rate (65%) than patients in TAU (40%) or BT (44%). Replicable
PIs may aid treatment selection and help streamline stepped models of care. For
most individuals who are depressed, the differences between existing treatments for
depression appears to be negligible. Thus, all else equal, lower intensity treatments
should be prioritized over more intensive ones. For individuals with a more severe
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course, greater functional impairment, and a higher vulnerability to depression, more
intensive interventions should be considered.
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INTRODUCTION
There is a wide variety of treatments for depression, and these treatments
differ in how intense they are in terms of the investment and resources required
from patients and mental health providers. Despite the availability of these different
types of interventions, current models for the delivery of mental health care for
depression are known to be inadequate. At one end of the spectrum, some patients
receive higher intensity interventions than they require to experience symptom
relief, for example undergoing antidepressant treatment or long-term psychotherapy
when they could experience comparable benefit from briefer therapies or lifestyle
changes (Lorenzo-Luaces, DeRubeis, & Bennett, 2015; Lovell & Richards, 2000).
Conversely, many patients do not receive the intensity of care that they might
require to experience symptom relief, for example receiving supportive listening
when they might benefit more from the combination of antidepressant medications
and an evidence-based psychotherapy (Kocsis et al., 2008; Lecrubier, 2007). It is
difficult to match patients to the appropriate level of care they need because there
are few variables that are known to affect treatment response (van Straten, Hill,
Richards, & Cuijpers, 2015), and mood disorders are extremely heterogeneous in
their presentation and prognosis (Lorenzo-Luaces, 2015; Parker, 2005). We describe
an approach to combining variables into a prognostic index (PI) that can be used
when selecting between treatments that differ in intensity.
It is well appreciated that even when two treatment are equally efficacious
there may be important subgroups of patients who would respond preferentially to
one of the treatments over the other (DeRubeis et al., 2014; Kang, Janes, & Huang,
2014; Kraemer, 2013; Wallace, Frank, & Kraemer, 2013). Even when one treatment
approach is known to be superior, on average, to another treatment or a control, it is
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still possible that the efficacy of the stronger treatment is confined to a subset of the
population and that patients can be matched to the intensity of care most
appropriate to them (Delgadillo, Moreea, & Lutz, 2016). For example, although on
average antidepressants are reported to be more efficacious than placebos, their
superiority over placebos seems to be limited to patients with more severe
depression (Barbui, Cipriani, Patel, Ayuso-Mateos, & van Ommeren, 2011; Fournier
et al., 2010; Khan, Leventhal, Khan, & Brown, 2002; Kirsch et al., 2008). Similar
findings have been reported for psychotherapy (Driessen, Cuijpers, Hollon, & Dekker,
2010). Although few would argue that these finding should be interpreted to mean
that antidepressants and psychotherapy are no more than placebo controls, it
appears that patients with non-severe depression stand to benefit as much from
interventions that are less intensive or less expensive than treatments that are more
intensive.
Stepped models of care for depression and other health conditions rely on the
logic that many patients can benefit from less intensive interventions before
requiring high intensity ones, and there is some empirical support for this
assumption. In a recent study comparing face to face cognitive-behavioral therapy
(CBT) to stepped care, there were no differences between the two treatments
conditions and most patients who recovered in stepped care did so in the less
intensive phases of treatments (Nordgreen et al., 2016). Although stepped models
of care represent an improvement over other traditional models of care, they could
be substantially streamlined if one knew, a priori, who is likely to respond to a low
intensity treatment and who is likely to require a stronger or more intensive
treatment. Given the findings suggesting that the efficacy of antidepressants and
psychotherapy is limited to patients with more severe depression, a logical
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recommendation for improving treatment delivery would be to start patients with
severe depression on a high intensity treatment like CBT or an antidepressant and,
for patients with mild to moderate depression, to start with a lower intensity
intervention. Indeed, the NICE Guidelines utilize severity as one of the main
variables guiding treatment selection (National Institute for Clinical Excellence,
2004). While this is an evidence-based approach to the care of individuals with
depression, it has as a notable limitation in that it relies on a single variable.
Findings from studies comparing psychotherapy, medications, and their
combination highlights the importance of considering the influence of multiple
variables when deciding between treatments of different intensities. For example, in
an individual patient data meta-analysis (IPD), comparing monotherapy with CBT or
interpersonal psychotherapy (IPT) to the combination of either psychotherapy and an
antidepressant, Thase et al. (1997) reported that combined therapy was not superior
to CBT or IPT monotherapy in mild depressions. However, combined treatment
yielded superior recovery rates (60%) than psychotherapy alone (19%) for patients
with severe and recurrent depression. Similarly, Hollon et al. (2014) reported that
the superiority of combined treatment with CBT and medications relative to
medications alone (72.6% vs. 62.5% overall) was limited to the subset of patients
with severe and non-chronic recurrent major depression, where the difference was
81.3% vs. 51.7%.
It would be hard to argue that combining two active treatments like
psychotherapy and antidepressants is not likely to yield stronger overall effects than
just using one of these treatments (Forand, Amsterdam, & DeRubeis, 2015). Indeed,
the findings of Hollon et al. (2014) and Thase et al. (1997) suggested that, overall,
there was a small advantage for the presumably stronger treatment approach (i.e.,

6

combination therapy) vs. the relatively weaker one (i.e., monotherapy with
medications or psychotherapy). However, it appears that this small average
difference was the product of a large difference in one group of patients and a small
or negligible difference in another group(s). A striking feature of these reports is that
the proportion of the sample that was expected to show a large advantage of the
stronger treatment approaches was rather low (32.7% for Thase et al.; 32.3% for
Hollon et al.). Despite this, the differences that were found between the combined
treatments versus the monotherapies in the respective studies were larger than what
is commonly reported in the treatment literature. An even more striking example of
the importance of considering more than one variable in examining the efficacy of a
strong vs. a weak (or no) treatment was provided by Nelson et al. (2013). These
authors explored moderator of response to placebo vs. antidepressants in a very
large sample of patients (N = 2283) with late-life depression. Overall, a minimal
difference between antidepressants and placebos was observed. For patients with
non-chronic depression, there were actually no differences between the two
treatments. However, a large differences (d = 0.70) was obtained for patients who
had chronic and severe depression.
Despite the fact that these studies are promising in that they suggest that
severity and an additional variable could be used to guide treatment decisions, there
is a series of issues associated with combining multiple moderator by treatment
interactions, as done by Thase et al. (1997), Hollon et al. (2014), and Nelson et al.
(2013). Individual variables may be weak moderators by themselves but, in
conjunction with other variables, may be part of an overall stronger moderator
variable. Illustrating this point, Cloitre, Petkova, Su, and Weiss (2016) explored
moderators of the efficacy of skills training + exposure vs. exposure + supportive
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listening vs. skills training+ supportive listening for post-traumatic stress disorder
(PTSD). In that trial, the skills training + exposure condition was superior to the
other two conditions overall, especially in regard to assessments that took into
account the follow-up. Although none of the six moderator variables that were tested
in interaction with treatment predicted outcomes, a composite variable was a strong
moderator of outcomes in the comparison of exposure only versus social skills
training only. A similar approach was recommended by Kraemer (2015) who
asserted that “if there are multiple [moderators] related to the same underlying
construct, these … should be combined in order both to increase the reliability of the
measurement of that construct and to avoid problems associated with
multicollinearity in combining them.” DeRubeis, Gelfand, German, Fournier and
Forand (2014) argued for the existence of one such construct when they discussed
patient response profiles. According to these authors, patients differ in the extent to
which they can benefit from active psychotherapy processes and strong treatment
approaches. Subsets of patients who are likely to improve much irrespective of
interventions, as is characteristic of samples of patients with depression, are unlikely
to reveal specific intervention effects.
Another way of framing the question of whether the active benefit of
treatments is circumscribed or especially pronounced in one patient group is in terms
of a prognostic index (PI). PIs can be thought of as predictive of patients’
symptomatology in a future time frame. This information can be considered absent
the consideration of what treatment will be provided. For example, patients with less
severe depression are more likely to recover from their depressive episode than
patients with more severe depression, irrespective of the treatment they receive.
However, information from a PI can also be used to determine the intensity level of
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care a patient should receive. Indices that reflect prognosis are also used in health
research to determine the intensity or an intervention or whether one is needed at
all. Summarizing findings from a prevention study in which the benefits were most
pronounced in a specific subgroup of patients, Garber et al. (2016) stated that
information “based on purely prognostic indices, allows for more efficient use of
resources and suggests possible prevention targets so as to increase the power of
the intervention.” (p. 2) A similar recommendation was made by Delgadillo et al.
(2016) who used a PI to predict the likelihood of experiencing clinically significant
improvement in a sample of patients with anxiety and depression from the
Improving Access to Psychological Therapies (IAPT) programme, which included lowintensity and high-intensity psychotherapy conditions (see also Saunders, Cape,
Fearon, & Pilling, 2016). When these authors stratified patients according to
predicted likelihood of improvement, they found differences in likelihood of
improvement across both treatments conditions and within each treatment condition.
Patients with the highest likelihood of improvement were likely to improve in anxiety
irrespective of high- (59%) vs. low-(56%) intensity treatment. By contrast, an
advantage of the high intensive interventions vs. low-intensity interventions was
observed (31% vs. 20%) for patients who had a lower likelihood of improvement.
In the context of a clinical trial in which there were no differences in outcome
overall between treatment as usual (TAU), stepped care starting with brief therapy
(BT) or stepped care starting with CBT (CBT), we hypothesized that prognostic status
would moderate this effect. Among patients who, based on pre-treatment
characteristics, are predicted to do well, few if any differences in outcome were
expected between these treatments. However, we predicted that for patients with a
poorer prognosis the more intensive CBT should outperform TAU and BT.
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METHODS
The aim of the trial from which these data were drawn was to compare TAU to
each of two stepped care regimens. One of the regimens began with a low intensity
treatment (i.e., BT) and the other began with a high intensity treatment (i.e., CBT;
Van Straten, Tiemens, Hakkaart, Nolen, & Donker, 2006). The trial was designed so
as to mimic conditions found in routine care settings. Patients were sampled from a
representative subsample of 7 of the 47 regional mental health care centers (MHCs)
that provide mental health care in the Netherlands.
Outpatients between the ages of 18 and 65 years (N = 5,219) were screened
for participation in the trial. Exclusion criteria were: the presence of psychotic or
manic symptoms, a thought disorder, dependence on hard drugs (patients with
alcohol abuse or dependence were not excluded), high suicide risk, or poor command
of the Dutch language. Patients who were not excluded on the basis of these criteria
were screened for the presence of mood and/or anxiety disorders with the INSTEL
screen, which is a Dutch modified version of the Goldberg-screen (Goldberg, Bridges,
Duncan-Jones, & Grayson, 1988; Tiemens, 1999). All remaining patients (i.e., those
who screened positive for a mood or anxiety diagnosis and did not meet exclusion
criteria, n = 1,608) were followed up for an at-home interview (baseline assessment)
by a trained research assistant to determine the presence of mood- and/or anxiety
disorders, using the composite international diagnostic interview (CIDI; Wittchen,
Robins, Semler, Cottler, & Organization, 1993). Of these patients, 214 could not be
reached. Patients in the original trial were eligible if they met the criteria for any of
the following DSM IV (American Psychiatric Association, 2000) disorders: MDD,
dysthymia, panic disorder, social anxiety, or generalized anxiety disorder. Of the
1,394 patients who were reached for interview, 214 did not have a DSM-IV mood or
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anxiety disorder present, 17 had poor command of the Dutch language, and 396
refused to participate in the study. Thus, in total, 702 patients consented and
participated in the parent study. In the present paper we focus on the 622 patients
who met criteria for MDD.
Brief therapy. In the 1980s, brief therapy (BT) was introduced in the
Netherlands as a remedy for lengthy waiting lists. In this study, BT was provided for
a total of 5 sessions with a maximum of 2 booster sessions in the six-month period
following treatment completion. During the first session, a scheme was used to
assess presenting problems (e.g., main symptom complaints, interpersonal
functioning, and life areas to be worked on). The aim of BT in this study was to
create hope by clarifying problems and emphasizing and strengthening the patient’s
own competence and coping skills.
Cognitive-behavioral therapy. In this study, CBT consisted of five modules
spanning 11-15 sessions: a) introduction (one session), b) providing information
about the aim and the procedure of the treatment and assessing patients’ cognitions
(three sessions); iii) changing cognitions by challenging them (three sessions); iv)
changing behavior by performing behavior experiments while challenging cognitions
(three sessions); v) integrating new behavior in patients’ lives by additional behavior
experiments (one to five sessions).
The TAU condition consisted of matched care as it was conducted in the
Netherlands at the time: an interdisciplinary mental health care team reviewed each
case and patients were assigned to the treatment that they were expected to benefit
the most from. Treatments varied by type (e.g., dynamic, supportive), format (e.g.,
group, online), and intensity (i.e., duration). TAU, BT, and CBT were considered as
first steps in a stepped-care model. Therefore, all patients were allowed to switch
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treatments, during or after treatment completion, if either the patient or the
therapist was convinced that the clinical effects were insufficient. In other words:
although the BT and CBT conditions had a set protocol and number of session
patients were allowed to ‘step up’ from these treatments or from TAU. Patients who
met the criteria for severe depression in any of the three treatment conditions were
allowed to receive antidepressant medication in addition to the psychological
treatment. Following the baseline assessment, initiation of treatment occurred after a
naturalistic waiting period (in days: TAU: M = 89, SD = 69; BT: M = 50, SD = 43;
CBT: M = 83, SD = 58).
Outcomes and missing data
Patients were interviewed at baseline and then every 3 months, irrespective
of the timing of treatment initiation and termination. The baseline and one-year
assessments, as well as the final follow-up, were conducted via face-to-face
interviews. The primary outcome for the current analyses was recovery at the final
follow-up, defined by the absence of MDD status. The final follow-up interview
occurred at least 18 months after enrollment in the study. The first 59 patients who
entered the study were followed for 24 months; subsequent enrollees were followed
for 21 months (n = 105) or 18 months (n = 256). In these analyses we controlled
for follow-up duration, although there was no indication that the follow-up time by
itself, or in any of the treatment conditions, was related to recovery status. We also
examined recovery at the one-year assessment.
Rates of missing data on baseline co-variates were low (all <10%, see table
1.1). At the end of the study 68% of the participants (n = 420) were available to be
interviewed. There were no statistically significant differences in lost-to-follow-up
(LTFU) between the three treatments (ps > .66). When comparing the 201
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participants who were LTFU with those who were reached for the final interview,
depressed patients who were LTFU were more likely to have had a recurrent course
(62.2% vs. 53.3%, χ2(1) = 4.66, p = .031). To address missing data and LTFU
issues, we used a non-parametric missing value imputation procedure using random
forests with the R package missForest (Stekhoven & Bühlmann, 2012). Imputation
via random forests has the appealing feature of producing a single dataset for
analysis and has been shown to yield a lower imputation error than the more
commonly-known approach of multiple imputation via chained equations (MICE; see
Stekhoven & Bühlmann, 2012; Waljee et al., 2013). To check for the potential that
missing data imputation influenced our results, we re-ran the analyses described
below with the listwise-deleted version of the dataset (n = 417). The results were,
by and large, quite similar so we report the results obtained with the imputed data.
Analytic approach
A total of 23 variables were available for analysis. These variables included
demographics, clinical variables, personality traits as assessed by the NEO Five
Factor Inventory (Costa & MacCrae, 1992), and the clinical subscales of the Dutch
translation of the Symptom Checklist 90 (Derogatis, 1996; Table 1.1). In choosing
which of these variables we would explore as predictors of treatment outcomes, we
cross-referenced a recent review by Kessler et al. (2016) on predictors of depression
treatment outcomes that have been replicated at least once. We also took into
account multicollinearity, redundancy, and observed variability. Thirteen of the 23
variables were thus retained (Table 1.1). To determine which of the 13 variables
would be included in our PI, as well as their weights in the algorithm that would be
used to predict recovery, we utilized a bootstrap ranking procedure with a 10-fold
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cross-validated LASSO (least absolute shrinkage and selection operator) penalty in
1,000 bootstrapped samples (see SparseLearner package; Guo et al., 2015).
LASSO approaches belong to the family of penalized regression models
(Tibshirani, 1996, 2011) and have been recommended and used in other efforts to
predict MDD status (Kessler et al., 2016). They are meant to address the shrinkage
that is expected to occur when using a model in a sample or population in which it
was not developed. Variables are standardized, all coefficients are shrunk, and those
that that are close to zero are set to zero. This is done by specifying a shrinkage
tuning parameter that sets an upper limit on the sum of the regression coefficients in
the final LASSO equation. The entirety of the LASSO solutions for all possible values
of Lambda can be given by a modification of the least angle regression algorithm. In
this procedure, a first variable is entered into the regression equation based on how
highly it correlates with the residual from the intercept. The coefficient for that
variable is increased, starting from zero, in the direction of the correlation until
another variable is more highly correlated with the residuals and the process
continues until all variables are in the model. The LARS algorithm can give all
possible LASSO solutions by setting some variables’ non-zero coefficient to zero. To
this effect, the LASSO can be used for variable selection (i.e., zero coefficients were
not selected). In the analyses we conducted with each of the 1,000 bootstrap
samples, we used 10-fold cross-validation to select, among a range of Lambda
values, the value that yielded the smallest estimate of the prediction error. This
procedure converges on a final LASSO solution in which the variables are given the
set of weights that minimizes prediction error. We refer to this estimate as the
patient’s value on the PI. Because the PI is derived for a prediction of a binary
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variable, it is in the form of log odds. To facilitate interpretation, we convert it to an
estimate of the probability of recovery (PI%).
We used the traditional interpretation of the c-statistic/area under the curve
to evaluate the performance of the PI in predicting depression recovery (Austin &
Steyerberg, 2012). To determine whether outcomes varied between the three
treatment conditions, we ran binary logistic regressions predicting outcomes at
follow-up with dummy variables for each of the two active treatment conditions (i.e.,
CBT vs. TAU and BT vs. TAU), the PI, and the respective interactions between the PI
and treatment condition. We conducted a parallel logistic regression comparing CBT
vs. BT. In these analyses we controlled for the duration of the follow-up phase (18,
21, or 24 months) and the number of treatment sessions the patient attended,
although the inclusion of these covariates did not affect the pattern of results. To
probe significant interactions, when they occurred, between the PI and treatment
condition, we used the Johnson-Neyman technique (Hayes & Matthes, 2009). The
Johnson-Neyman technique is an alternative to the commonly-used method of
probing interactions between a moderator and a predictor by calculating slopes at
+/1 standard deviation of the mean of the moderator variable. It gives a value of the
moderator at which the significance of the predictor on outcome changes. In our
analyses, the Johnson-Neyman would help us establish a point in the prognostic
index at which treatment effects begin to be evident.
RESULTS
Descriptive statistics are presented in table 1. As would be expected given the
null results obtained in the full sample in the parent trial, there were no statistically
significant differences in the rate of MDD recovery between TAU (68.4%) and either
of the stepped care conditions (BT = 74.9%, OR = 1.30, B = 0.34, SE = 0.23, χ2 =
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1.33, p = 0.25; CBT = 75.0%, OR = 1.41, B = 0.34, SE = 0.22, χ2 = 2.53, p =
0.11). Five of the 13 potential predictor variables submitted to the LASSO procedure
were retained. Being unemployed, having more severe symptoms of depression,
higher levels of hostility, and having more sleep problems predicted a lower
likelihood of recovery. Higher levels of extraversion/positive emotionality were
associated with a higher likelihood of recovery. Table 2.1 shows the standardized
beta weights assigned to these variables by the LASSO model, along with the results
obtained when the five variables were entered into a single logistic regression
predicting likelihood of recovery. The effects of the bootstrapped LASSO procedure
on the model coefficients can be observed by comparing the LASSO coefficients to
the respective betas in the logistic regression. For example, the model coefficient for
unemployment, which was the highest in each of the modeling approaches, shrank
from -0.62 in the standard regression to -0.48 in the LASSO. By contrast, little
shrinkage was evident in the coefficient for severity (from -0.18 to -0.16), which was
the lowest in each of the approaches. The resulting PI, generated from the LASSO,
evidenced fair predictive accuracy (c = 0.73, 95% CI = 0.68 – 0.77, p < 0.001).
The PI was developed by predicting treatment outcomes ignoring the main
effect of treatment condition on outcomes, which, albeit small and not statistically
significant, was in the expected direction. Before examining whether the PI was
related to outcomes across the treatments, we carried out a series of analyses to
rule out the possibility that there was a systematic influence of treatment condition
on the PI. First, we evaluated the treatment comparisons in a regression that
contained the five variables selected previously: unemployment status, depression
severity, hostility, sleep problems and extraversion. The inclusion of these effects in
a model containing all the prognostic variables did not affect their statistical
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significance or the strength of their predictive relation vis a vis outcome. We then
examined whether the PIs themselves differed between the treatment conditions and
found no differences (F(2, 618) = 0.95, p = 0.39). Taken together, these results
suggest that treatment assignment did not influence the PI.
In the primary analyses predicting recovery at follow-up, the test of the
interaction of the PI and the CBT vs. TAU contrast was significant. The direction of
the effect indicated that, consistent with our hypothesis, the poorer the overall
prognosis, the greater the advantage of CBT relative to TAU (OR = 1.91, 95% CI:
1.18 – 3.10, B = 0.65, SE = 0.25 χ2 = 7.00, p = 0.008). The BT/TAU contrast,
however, did not interact with the PI in the prediction of outcome (OR = 0.94, 95%
CI: -0.601 – 0.49, B = 0.06, SE = 0.28, χ2 = 0.05, p = 0.83). This pattern was not
evident in the data from the 1-year assessment (all ps > .35).
The Johnson-Neyman technique was employed to follow up the significant
interaction of the PI with the CBT/TAU contrast at follow-up. The result of this
procedure suggested a cutoff on the PI that reflected a 63% likelihood of recovery,
and which divided the sample into the 23% with the worst prognoses (i.e., with PI%
< 60%) and the 77% with better prognoses (i.e., with PI% > 60%). Of the patients
with better prognoses, 81% recovered and, per Johnson-Neyman, there was no
difference between the conditions in recovery rates (see Figure 1). By contrast,
among the patients with poorer prognoses, a significantly higher percentage
recovered in CBT (65.2%) relative to TAU (39.7%; OR = 2.82, 95% CI: 1.24 – 6.20,
B = 1.04, SE = 0.40, χ2 = 4.01, p = 0.045). In the BT condition, the recovery rate
among patients with poor prognoses, 43.5%, was similar to what was observed in
the TAU condition.
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To assess whether any single variable unduly influenced the PI, we
recalculated it five times, each time removing one of the five variables. The results
remained the same: there was an interaction between the PI and the CBT vs. TAU
contrast (ORs > 1.69, ps < 0.013). This interaction was not present in the context of
the BT vs. TAU contrast (ps < 0.60). We also tested the interactions between
treatment condition and each of the five patient variables separately. None of the
interaction effects was significant (all ps > 0.09).
DISCUSSION
We described a procedure that yields a multi-variable prognostic index that
can be used in determining which patients are most likely to benefit more from a
high intensity intervention, relative to a lower intensity one. We tested this
procedure in the context of a randomized trial of TAU versus BT versus CBT, focusing
on the patients in the study with a diagnosis of MDD. Despite the trial being
adequately powered to detect moderate differences and despite the fact that the
three treatments differed in intensity, across all patients there were only small,
nonsignificant between-treatment differences in outcomes. Using our prognostic
index, we identified a subgroup of patients – those with the worst prognoses – for
whom the effects of CBT were substantially greater than those of TAU or BT. The
TAU and BT treatment arms in this study were conducted in a naturalistic context in
which the aim was to treat patients to improvement, even if this required
augmenting the patient’s original treatment. Thus, it is noteworthy that large
differences between the interventions were observed in the subset of patients with
poorer prognoses, according to our index. To put this in context, the difference
between CBT and TAU that we found (OR = 2.87) is outside the 95% CI of estimates
of comparisons of CBT vs. TAU reported in the latest meta-analysis exploring long-
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term outcomes between psychotherapies (Karyotaki et al., 2016). This suggests the
effect we found is not negligible.
There has been great interest in the use of patient characteristics to match
patients to the treatments that might be most suitable to them, often in the context
of treatment options of similar high intensity that are known to be approximately
equally effective (e.g., CBT, IPT, and antidepressant medications; (DeRubeis et al.,
2014; Huibers et al., 2015; Kang et al., 2014; Kraemer, 2013; Wallace et al., 2013).
Somewhat less attention has been paid to the use of information about patient
characteristics to assist in the matching of patients to the level of intensity of care
that is appropriate to them (Delgadillo, Moreea, & Lutz, 2016). The method we have
described provides a demonstration of how a statistical method could be used to
achieve this aim. The first step that is needed is the development of a prognostic
algorithm estimating the likelihood of being free of MDD at a later point in time. We
accomplished this by modeling MDD status at follow-up, ignoring treatment
assignment. This appeared to be reasonable approach in a trial such as this one in
that there were no statistically significant differences in outcomes between the
treatments. An analogous example is provided by Huang et al. (2006) in the use of
breast conservation therapy (BCT). They examined the risk of cancer recurrence as a
function of patients’ score on a previously-developed prognostic index (Chen et al.,
2005) in BCT, relative to mastectomy plus radiation. Although BCT had previously
been found to yield a slightly higher risk of recurrence relative to the higher intensity
mastectomy plus radiation, for patients with good prognoses (a majority of those in
the sample), there were no differences in recurrence rates between the two
condition. For patients who were highest on the risk index, rates of relapse were
substantially higher with BCT group (61%) relative to mastectomy plus radiation
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(19%). The similarity of this finding with our finding as well as those of Hollon et al.
(2014), Nelson et al. (2013), and Thase et al. (1997) suggest that across areas of
health care, prognostic status may serve to moderate the efficacy of higher versus
lower intensity interventions (see DeRubeis et al., 2014b). For most patients, there
might be little if any advantage of engaging in the higher intensity treatments. Even
so, a small and potentially identifiable subgroup of patients could experience
considerable benefit from higher intensity treatments.
An alternative approach to developing PIs, as suggested by Kessler et al.
(2016), is to develop risk models based on variables that are known, from
naturalistic studies, to predict treatment response. This risk estimate could then be
tested as a moderator of outcomes in a comparative clinical trial. Kessler et al. argue
that this approach is more valid than one based, as is the approach we used, on the
relations derived from a clinical trial. Even if they are correct, one limitation is that
there might not, in a given context, be convergence on the variables collected in
epidemiological studies and clinical trials. Moreover, it may be difficult to generalize
from epidemiological data to populations of patients who meet MDD criteria in clinical
trial samples, as the latter tend to be more severely impaired, on average (WiltseyStirman, DeRubeis, Crits-Christoph, & Brody, 2003; Zimmerman et al., 2016).
Variables that predict differential response to two treatments (i.e.,
prescriptive or moderator variables) are difficult to identify, especially in studies
underpowered for this purpose, including most published clinical trials. By contrast,
prognostic variables are easier to identify in that they require less statistical power,
may be easier to replicate, and may be derived from more naturalistic contexts. The
variables that were included in our prognostic index, depressive symptom severity,
unemployment status, sleep complaints, hostility, and extraversion, have been found
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to predict outcomes in other investigations. Symptom severity (Driessen et al.,
2010; Fournier et al., 2010; Khan et al., 2002; Kirsch et al., 2008), employment
status (Delgadillo et al., 2016; Jarrett et al., 2013; Rush, Wisniewski, Warden, & et
al., 2008; Trivedi et al., 2006), and sleep complaints (Andreescu et al., 2008; Dew
et al., 1997; Troxel et al., 2011) have been directly implicated as predictors of
outcome in depression. The various constructs captured by the measures of hostility
and extraversion – negative affect, low positive emotionality, difficulty in
interpersonal relationships, and overall maladaptive personality traits— have also
been reported to predict outcomes across various investigations (see Kessler et al.,
2016). These variables have in common the fact that they capture vulnerability to
depression, severity, and impairment associated with MDD. Less intensive
treatments like BT and TAU may not be sufficient to address the vulnerability and
level of illness severity that patients with a poorer prognosis have.
It is widely accepted that all evidence-based psychotherapies for depression
are equally efficacious (Barth et al., 2013; Cuijpers et al., 2014; Cuijpers, van
Straten, Andersson, & van Oppen, 2008). However, insofar as comparisons of
psychotherapies for depression have been conducted with populations that include a
high proportion of patients who are expected to improve irrespective of treatment
type, relative differences in the potencies of psychotherapies may have been
obscured. Providing support for this conjecture, the efficacy of psychotherapy
relative to controls differs as a function of symptom severity (Driessen et al., 2010).
Moreover, in several RCTs in which between-treatment differences were not found in
the full sample, differences were identified in subsamples that comprised the more
severely depressed patients (Dimidjian et al., 2006; Driessen et al., 2014; Elkin et
al., 1995; Luty et al., 2007).
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Although we found differences between CBT and both BT and TAU, it is worth
noting that differences emerged in the follow-up phase of the study and were limited
to a relatively small proportion of the sample. Regarding the first point, it is possible
that differential effects of psychotherapy are most evident in the long-term (Bell,
Marcus, & Goodlad, 2013; Bockting, Hollon, Jarrett, Kuyken, & Dobson, 2015; Cloitre
et al., 2016) in that shorter term outcomes may index remoralization or nonspecific
effects. Longer term outcomes may reflect whether patients’ underlying vulnerability
to psychopathology was addressed or whether they acquired tools from therapy to
deal with their problems (Bell, Marcus, & Goodlad, 2013). Regarding the second
point, in other instances in which significant differences have been reported in
subgroups but not in full samples, the subgroups have tended to constitute a
minority of the sample (Hollon et al., 2014; Nelson et al., 2013). Though it has been
recognized that most individuals who meet the criteria for MDD show high rates of
response in any evidence-based treatment, this observation has not been
incorporated into most guidelines for the treatment of depression. For example,
Middleton, Shaw, Hull, and Feder (2005) argue that while the UK’s NICE guidelines
are clear on how to best treat severe depression, there is little guidance available on
how to treat mild to moderate depression most efficiently. Thus, stepped care
models that begin with a low-intensity intervention, perhaps an intervention of even
a lower intensity than the BT implemented in the present study, should be
investigated further. Exercise, unguided self-help, and internet-based
psychotherapies all are promising interventions in this regard. Although there is little
evidence that these interventions are superior to high intensity interventions for
patients with mild to moderate MDD, they might be preferable in that they achieve
similar outcomes with lower costs.
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Table 1.1 Baseline demographic, personality, and clinical characteristics of subjects randomized to treatment as usual (TAU), brief therapy
(BT), or cognitive-behavioral therapy (CBT)
TAU
Female

BT

CBT

%

%
66%

(n)
(154)

%
62%

(n)
(110)

%
59%

(n)
(123)

2.17

0.34

6%

(13)

10%

(16)

14%

(27)

7.51

0.02

10%

11%

(24)

13%

(21)

10%

(19)

0.69

0.71

9%

36%

(77)

30%

(48)

31%

(57)

2.04

0.36

9%

6.47

0.37

10%

None

12.6%

(26)

9.90%

(16)

11.7%

(22)

Lower

39.1%

(84)

43.80%

(71)

46.3%

(87)

Middle

38.1%

(82)

30.20%

(49)

30.9%

(58)

High

10.7%

(23)

16.00%

(26)

11.2%

(21)
4.12

0.85

8%

a

Dutch immigrant

a,b

Problematic drinking

b

Unemployed||
Educational attainment||

Somatic illnesses (#)||
1.00

30.10%

(65)

32.70%

(53)

30.30%

(57)

2.00

16.70%

(36)

20.40%

(33)

18.60%

(35)

3.00

9.70%

(21)

8.60%

(14)

9.60%

(18)

4+

χ2

p

miss.

12.50%

(27)

7.40%

(12)

8.50%

(16)

Anxiety co-morbidity||

44.90%

(105)

45.80%

(82)

48.60%

(101)

0.63

0.73

Severe MDD (CIDI)||

39.50%

(90)

38.20%

(66)

41.80%

(84)

1.97

0.74

Recurrent MDD (CIDI)||

57.70%

(135)

49.20%

(88)

60.60%

(126)

5.43

0.07

M
35.98

SD
(10.29)

M
36.53

SD
(10.27)

M
36.63

SD
(9.9)

F
0.26

p
0.77

9.22

(3.85)

9.26

(3.85)

9.29

(3.66)

0.02

0.98

9%

13.29

(6.31)

13.96

(7.03)

14.27

(6.77)

1.13

0.32

9%

Age||

3%

Symptom Checklist 90
Sleep||
Agoraphobia

a,c
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Anxiety

c

Depression

c

Hostility||
Insufficiency

a,c

Interpersonal
sensitivity
Somaticc
Other

c

a,c

26.06

(8.85)

26.18

(8.97)

27.41

(8.77)

1.35

0.26

9%

48.58

(12.35)

47.99

(14.24)

49.15

(12.68)

0.34

0.71

9%

12.95

(5.37)

12.49

(5.28)

12.44

(5.36)

0.57

0.57

9%

24.93

(7.51)

24.11

(7.95)

25.33

(7.57)

1.14

0.32

9%

42.48

(15.56)

40.87

(15.06)

43.87

(14.96)

1.69

0.19

29.51

(9.55)

28.24

(9.52)

28.34

(9.14)

1.12

0.33

9%

19.32

(5.87)

18.79

(5.92)

19.47

(6.16)

0.61

0.54

9%

9%

NEO
Conscientiousness

a

3.25

(1.95)

2.79

(1.7)

3.11

(1.84)

2.22

0.11

9%

Agreeableness||

4.43

(2.06)

4.27

(2.)

4.21

(2.)

0.49

0.62

9%

Extraversion||

2.23

(1.83)

0.18

0.84

9%

(1.13)

(1.94)
(1.07)

(1.84)

7.77

3.22
1.89

3.12

Neuroticism||

7.88

(1.11)

0.55
0.58
9%
4.99
(1.87)
4.80
(2.07)
5.39
(1.9)
3.22
0.04
9%
Note. % miss – percentage missing data at baseline. MDD – major depressive disorder. CIDI - Composite International Diagnostic Interview.
NEO- NEO Five Factor Inventory. || variable explored as a predictor of outcomes. A – variable not explored as a predictor of outcomes
because no prior research suggests it is predictive of outcomes in depression treatment, b - variable not explored as a predictor of outcomes
because there was low variability, c - variable not explored as a predictor of outcomes because it was co-linear with some variables and
represented by other variables
Openness||
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Table 1.2 LASSO solution for predictor variables used in prognostic index (PI)
predicting recovery at follow-up and model estimates from logistic regression using
these variables
LASSO

B

SE

OR

Unemployment status

-0.48

-0.62

0.20

0.54

Depression severity

-0.16

-0.18

0.11

0.84

Hostility (SCL)

-0.38

-0.45

0.10

0.64

***

Sleep complaints (SCL)

-0.27

-0.31

0.11

0.73

**

0.29

0.39

0.11

1.47

***

Extraversion (NEO)

**

Note: Vertical lines separates results of LASSO solution from results of logistic
regression. *** p < 0.001, ** p < 0.01, * p <0.05. SCL: Symptom Checklist 90-R
subscale. NEO: NEO Five Factor Inventory subscale.
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Figure 1.1 Recovery rates at follow-up between treatment as usual (TAU), and
stepped care starting with brief therapy (BT) or cognitive-behavioral therapy (CBT)
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ABSTRACT
Little is known about the variability of the alliance–outcome correlation across
identifiable client subsets. This question was explored in a sample of 60 clients
receiving cognitive therapy for depression, from which an overall correlation of .23
was observed between alliance ratings and subsequent symptom change. We
examined interactions between the observer-rated version of the Working Alliance
Inventory–Short Observer-Rated version (WAI–O; Tracey & Kokotovic, 1989) and
client demographics, features of depression, personality, and other clinical features
in predicting subsequent symptom change. After corrections for multiple
comparisons, interactions between the WAI–O and the number of prior depressive
episodes, as well as the severity of baseline anxiety symptoms, were significant
predictors of symptom change. When both interactions were controlled for, number
of prior depressive episodes emerged as a statistically significant moderator. The
alliance predicted outcome in the subgroup of clients with 0–2 prior episodes (r =
.52), but not in those with 3 or more prior episodes (r = .02). These findings were
obtained despite similar univariate distributions on the alliance and symptom change
in the 2 subgroups. Differences that were observed in the predictive relation of
alliance to outcome as a function of number of prior episodes suggest that different
therapy processes may account for change in these subgroups. If the pattern
observed in the present study is replicated, it would suggest that the alliance–
outcome association has been both under- and overestimated.
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INTRODUCTION
Estimates from meta-analytic reviews indicate a small- to medium-sized
association between the therapeutic alliance and treatment outcomes (Horvath, Del
Re, Flückiger, & Symonds, 2011). Although methodological issues in research on the
alliance have prompted questions about the direction of the causal influence in the
relation between symptom change and the alliance (e.g., DeRubeis, Brotman, &
Gibbons, 2005), the alliance remains an important construct in psychotherapy
research and practice. A relatively unexplored question is to what extent alliance–
outcome associations are moderated by identifiable client characteristics.
Research on client characteristics and the alliance has, for the most part,
focused on predictors of the alliance (Castonguay, Constantino, & Holtforth, 2006) or
on the alliance as a mediator of the relationship between client characteristics and
outcome (e.g., Shahar, Blatt, Zuroff, & Pilkonis, 2003). Less severe clinical pictures,
fewer difficulties in interpersonal relationships, and improvement during therapy tend
to be associated with higher alliance scores. A separate question, which is the focus
of this report, is whether client characteristics moderate the alliance–outcome
relationship. Using simulations, DeRubeis, Gelfand, German, Fournier, and Forand
(2013) have shown that the magnitude of the association between process variables
and outcome can be heavily influenced by characteristics of the client sample in
which the correlation is studied. In a meta-analysis that illustrates this point, Sharf,
Primavera, and Diener (2010) found that the association between the alliance and
study dropout tends to be smaller in studies that contain higher proportions of clients
who completed high school.
Although moderation of the alliance–outcome relationship has been explored
in other meta-analyses (e.g., Del Re, Flückiger, Horvath, Symonds, & Wampold,
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2012), a meta-analysis allows one to make inferences about samples, not
individuals. To our knowledge, only Falkenström, Granström, and Holmqvist (2013)
have used individual patient data to test client variables as moderators of the
alliance–outcome relationship. The objective of the present study is to identify client
characteristics that moderate the alliance–outcome correlation in cognitive therapy
(CT) for depression. We explored demographic variables, personality traits, and
other clinical features that have been hypothesized to affect the alliance or its
relation to outcome.
Insofar as demographic features, such as gender, age, and marital status,
influence clients’ perceptions of interpersonal relationships, these may interact with
the alliance in promoting change (see Flückiger et al., 2013). Personality traits have
also been explored in relation to the alliance and improvement in psychotherapy. Del
Re et al. (2012) found that the percentage of clients with personality disorders in
studies of the alliance was unrelated to the strength of the alliance–outcome
relationship. However, in a large, heterogeneous sample of mental health clinic
outpatients, Falkenström et al. (2013) found that the alliance–outcome relationship
was stronger in clients with personality problems. It has also been suggested that in
depression, the alliance might be of particular importance with clients with more
severe, chronic, and recurrent forms (see Arnow et al., 2013). Finally, features that
reflect the complexity of a client’s clinical picture, including, for example, comorbid
anxiety (Horvath et al., 2011) or substance use (Flückiger et al., 2013), have been
considered potential moderators of the alliance–outcome associations.
METHOD
Data were drawn from the CT arm (N = 60) of a randomized controlled trial
comparing CT versus antidepressants in the treatment of moderate to severe major
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depressive disorder (DeRubeis et al., 2005). The study was approved by the local
institutional review boards.
Measures
Beck Depression Inventory—Second Edition (BDI–II; Beck, Steer, &
Brown, 1996). Depressive symptoms were assessed with the BDI–II, a 21-item
self-report measure that was completed by all clients before the start of each
therapy session as well as at the end of the 16-week treatment period. When a client
did not provide an end-of-treatment BDI–II, which happened for nine dropouts, we
used the last available BDI–II score to represent outcome on this instrument.
Working Alliance Inventory–Short Observer-Rated version (WAI–O;
Tracey & Kokotovic, 1989). On the WAI–O, observers rate 12 items assessing
agreement in the goals and tasks of therapy and the affective bond on a 7-point
scale (from 0 = never to 6 = always; range: 0–72). Ratings used in the present brief
report constitute a subset of the ratings used by Webb et al. (2011). For each of the
59 clients who completed at least three sessions of CT, two raters (from a pool of
five) rated an early session of therapy (Session 3 if available; otherwise Session 2 or
4). Raters were assigned sessions according to a balanced incomplete block design.
Pooled ratings for each session yielded estimates of the quality of the alliance. Raters
received training on the WAI–O and were unaware of the treatment outcomes. They
achieved adequate reliability (ICC = .73; see Webb et al., 2011, for a more thorough
description of the procedure).
Potential moderators
Demographics. We included age (in years), sex, years of education, marital
status (married or cohabiting with a partner vs. single), and estimated IQ (derived
from the Shipley-Harford Living Scale; Shipley, 1940).
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Personality. We included the five factors of the NEO Five-Factor Inventory.
Openness, Conscientiousness, Extraversion, Agreeableness, and Neuroticism (Costa
& McCrae, 1992) and the number of Cluster B and C symptoms individuals endorsed
in the Structured Clinical Interview for DSM–IV Axis II disorders (Gibbon, Spitzer, &
First 1997).
History and features of depression. This set consisted of depression
severity (Hamilton Rating Scale for Depression; Hamilton, 1960), atypical
depression, duration of current episode, age at first episode, number of prior
episodes, and number of prior depression treatments (all assessed by the Structured
Clinical Interview for DSM–IV–TR Axis I Disorders; First, Spitzer, Gibbon, & Williams,
2001).
Other clinical features. We also included number of life events (Psychiatric
Epidemiology Research Interview Life Events Scale; Dohrenwend, Askenasy,
Krasnoff, & Dohrenwend, 1978), history of substance abuse (from the Structured
Clinical Interview for DSM–IV–TR Axis I Disorders interview), severity of anxiety
symptoms (Hamilton Anxiety Rating Scale; Hamilton, 1959), hopelessness (Beck
Hopelessness Scale; Beck, Weissman, Lester, & Trexler, 1974) and total score on the
Attributional Style Questionnaire (ASQ; Peterson et al., 1982).
Analytic plan
Continuous variables were centered at their mean. Binary ones were coded
±0.5. Outliers at three or more standard deviations were winsorized, and nonnormal
variables were transformed to meet linearity assumptions. The outcome variable was
residualized subsequent change in depressive symptoms, calculated as the difference
between the BDI–II score from before the start of the rated session and the end-oftreatment BDI–II score, controlling for the session BDI–II score. For each of the 23
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potential moderators, we ran regression models predicting residualized change from
(a) the WAI–O, (b) the main effect of the potential moderator, and (c) the
interaction of the potential moderator and the WAI–O. We corrected for multiple
comparisons with the Benjamini–Hochberg method (Benjamini & Hochberg, 1995),
using a false discovery rate of p < .05. After this correction, potential moderators
and their respective interactions with the WAI–O were included together in a
regression model predicting subsequent change. We used Pothoff’s modification to
the Johnson–Neyman technique to assess the effect of interactions (Hayes &
Matthes, 2009). This yields an estimate of the point along the values of the
moderator at which the predictor–criterion association transitions between
statistically significant and nonsignificant.
RESULTS
Table 2.1 presents descriptive statistics as well as the correlations of all 23
pretreatment variables with the WAI–O and subsequent change. By itself, the WAI–O
was related to subsequent symptom change, β = 0.23, χ2(1) = 11.31, p < .001.
The main effect of none of the 23 variables was significant in the prediction of
symptom change. However, 4 of the 23 tests of moderation (interaction with the
alliance) were significant at the p < .05 level (uncorrected). The alliance–outcome
relationship became stronger with increasing severity of baseline anxiety symptoms,
β = 0.23, χ2(1) = 14.89, p < .001; increasing levels of self-reported
conscientiousness, β = 0.22, χ2(1) = 4.60, p = .03; lower scores on measured IQ, β
= −0.19, χ2(1) = 4.68,p = .03; and fewer prior episodes, β = −0.30, χ2(1) =
18.45, p < .001. After we corrected for multiple comparisons, only the interactions
with anxiety severity and number of prior depressive episodes remained significant.
When a model predicting subsequent change contained the WAI–O, these two
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moderators, and their interactions, only the interaction between the WAI–O and prior
episodes remained significant, β = −0.25, χ2(1) = 4.20, p = .04. The interaction
between the WAI–O and anxiety was reduced to a trend, β = 0.40, χ 2(1) = 3.07, p =
.08.
The region of significance for predicting outcome with the WAI–O was
estimated by the Johnson–Neyman technique as all values of prior episodes below
1.89. Figure 2.1 provides a graphical representation of this association. As depicted
in Figure 2.2, among clients with zero to two prior episodes of depression, the WAI–
O predicted symptom change, r = .52, 95% confidence interval (CI) [.22, .73], p =
.001, and its prediction of symptom change was higher than in the group with three
or more prior episodes, r = −.02, 95% CI [−.41, .38], p = .89. The difference
between these correlation coefficients was statistically significant (Z = -2.19, p = .03). These relationships held for the WAI–O total and were not specific to either of
its subscales. The means of WAO–I scores were similar for those with zero to two
versus three or more prior episodes (51.2 vs. 53.6), t(57) = 1.65, p = .10, as were
the variances (5.23 vs. 5.67), F = 0.95, p = .34. Residualized change in BDI–II score
was also similar between the groups (11.42 vs. 13.20), t(57) = −0.80, p = .43;
variances: 8.64 versus 8.40, F = 0.18, p = .67.
DISCUSSION
In this sample, the overall alliance–outcome correlation of .23 was well within
the range of values produced by the latest meta-analysis (Horvath et al., 2011).
However, the size of this relation varied substantially as a function of the number of
prior episodes of depression reported at baseline. For clients with fewer than three
prior depressive episodes, the alliance–outcome correlation was substantially higher
than what is commonly observed in the literature. In contrast, in the sample of 24
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patients who had experienced three or more episodes, the alliance was not predictive
of symptom change. If replicated, this would suggest that by ignoring interactions
with patient variables, the alliance–outcome correlation can be both over- and
underestimated.
Tests of interaction effects require larger sample sizes than tests of main
effects do. The present study could thus be considered underpowered. In an
adequately powered study, we may have identified more moderators. The small
sample also precluded tests of therapist effects or the interaction of therapist and
client characteristics. Because of the paucity of research on interactions of client
characteristics and the alliance, we conducted exploratory analyses of multiple
potential moderators.
Despite these limitations, the study makes a novel contribution in finding a
significant interaction between the alliance and an important client variable in
predicting outcome. That this finding was obtained after correcting for multiple
comparisons and that it remained significant after controlling for several potential
confounds suggest it may be robust. The data were well-suited for our research
question, as they allowed for the control of temporal confounds such as prior
symptom change, and that the alliance ratings were obtained from observers who
were unaware of the treatment outcomes as well as most client characteristics.
Additionally, using observer ratings avoids the potential for the shared variance
confound that exists when clients’ ratings are used both for the alliance and for the
outcome variable. It is important to note that the interaction between prior episodes
and the alliance in the prediction of outcome could not be accounted for by
differences in the means or variances of the measures of alliance or outcome. Thus,
it does not appear to be a statistical artifact.
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Ma and Teasdale (2004) found evidence that patients with three or more prior
episodes of depression report more childhood adversity, an earlier age of first onset
of depression, and depressive relapses that more often came out of the blue when
compared with patients with less recurrent forms of depression. Additionally, it is this
group with three or more prior episodes of depression that evidences the benefit of
an intervention to prevent relapse. These findings may be taken to suggest that
patients who have had zero to two versus three or more prior depressive episodes
represent essentially different subgroups. Consistent with this research, less
recurrent forms of depression may be more reactive to negative as well as positive
life events, whereas more recurrent forms may indicate the presence of ruminative
and autonomous depressogenic processes. Similarly, Wakefield and Schmitz (2013)
argued that the recurrence of depressive episodes can be understood as an indicator
of underlying pathology in the individual, as opposed to reactions to life stressor and
contextual variables. It is possible that patients with less recurrent depressions tend
to be more reactive to positive and negative interpersonal interactions, including
those that are captured in assessments of the therapeutic alliance. For those with
recurrent depressions, however, the relationship with their therapist, as is true of
their interpersonal experiences generally, might have little impact on the course of
their depressive episode, relative to therapy processes that address the intrapsychic
processes that are known to be especially problematic in this group.
Although it is widely held that clients are helped differentially by different
aspects of therapy, few findings in the literature speak to this. The existence of an
interaction between prior depressive episodes and the alliance in the prediction of
subsequent symptom change, as well as other interactions between process
variables and client characteristics (e.g., Strunk, Brotman, DeRubeis, & Hollon,
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2010), adds empirical support to this clinical intuition. However, these findings also
present a challenge for psychotherapy research and theories of the mechanisms of
therapeutic change. Indeed, the existence of substantial moderators of process–
outcome correlations might be responsible for the difficulty in identifying
mechanisms of change in therapy (DeRubeis et al., 2013). Therapist variables are
also likely to interact with client characteristics and the alliance to influence outcome.
Thus, in the interest of achieving a better and more nuanced understanding of
mechanisms of change in treatment, there is a great need to explore client and
therapist variables that moderate this and other process–outcome relationships.
Consistent with recent calls to personalize treatments according to patient
characteristics (DeRubeis et al., 2014), this type of research would facilitate the
tailoring of psychological interventions to specific individuals.
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Table 2.1 Characteristics of the sample and bivariate associations between client
baseline characteristics, WAI-O ratings and subsequent change
WAI-O

Symptom
change

M or

(SD)

r

r

%

or n

WAI-O

52.5

(5.41)

--

0.23***

Subsequent Change in BDI

12.2

(8.51)

0.23***

--

Years of education

14.6

(2.50)

-0.10

0.08

Female %

58%

35

0.02

0.02

Age

40.3

(11.51)

0.03

0.06

Married or cohabiting %

30%

18

-0.05

0.17

IQ

109.7

(10.21)

-0.12

0.17

Agreeableness (0 – 48)

28.4

(6.38)

0.27

0.12

Conscientiousness (0 – 48)

26.6

(8.63)

0.17

0.07

Extraversion (0 – 48)

20.7

(6.53)

0.08

0.01

Neuroticism (0 – 48)

32.4

(7.56)

0.00

0.05

Openness (0 – 48)

28.4

(6.72)

-0.06

0.15

Demographics

Personality
NEO - FFI
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Number of Cluster B Criteria

2.4

(2.49)

-0.08

-0.24

Number of Cluster C Criteria

4.3

(3.50)

-0.11

-0.01

Met atypical depression criteria %

28%

17

0.01

0.00

Depression severity – HRSD (0–53)

23.9

(3.08)

-0.20

-0.14

Duration of current episodes (mo.)

31.4

(35.23)

-0.19

-0.04

Number of prior episodes

2.3

(2.00)

-0.19

0.01

Prior antidepressant treatments

1.7

(1.81)

-0.26

-0.04

Age of onset of first episode

24.2

(12.95)

0.17

0.09

Number of life events – PERI (0 – 102)

6.8

(4.37)

0.14

0.15

Past history of substance abuse %

28%

17

-0.07

0.14

Attributional Style - ASQ

0.36

(3.05)

-0.23

-0.14

Anxiety severity – HAM-A (0 – 48)

16.6

(5.93)

-0.17

0.09

Hopelessness – BHS (0 – 20)

11.2

(5.16)

0.18

0.08

History of depression

Other clinical features

Note. WAI – O – Working Alliance Inventory, Observer ratings, Symptom change –
residualized change in the BDI, IQ – Intelligent Quotient, HRSD – Hamilton Rating
Scale for Depression, NEO – FFI – NEO – Five Factor Inventory, PERI – Psychiatric
Epidemiology Research Interview Life Events Scale, ASQ – Attributional Styles
Questionnaire (positive – negative), HAM-A – Hamilton Anxiety Rating Scale, BHS –
Beck Hopelessness Scale.

p <.001. For dichotomous variables, point-biserial

***

correlations with the WAI-O and subsequent change are provided. For continuous
variables, Pearson product-moment correlations with the WAI-O and subsequent
change are provided.
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Figure 2.1 Predicted association between therapeutic alliance and subsequent
symptom change across prior depressive episodes. BDI = Beck Depression
Inventory—Second Edition.
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Figure 2.2 Observed relationship between early ratings of the therapeutic alliance
and subsequent change, by prior number of episodes. BDI =Beck Depression
Inventory—Second Edition.
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ABSTRACT
A prior study suggested that, in cognitive-behavioral therapy (CBT), the association
between the working alliance and depression improvement varies as a function of
prior history of depression. We sought to replicate these findings in CBT and extend
them to short-term psychodynamic supportive psychotherapy (SPSP) in a sample of
patients who were randomized to one of these treatments and were administered the
Helping Alliance Questionnaire (N = 282). Overall, the alliance was a predictor of
symptom change (d =0.37, p < .001). In SPSP, the alliance predicted symptom
change for patients with 0-1 episodes (d = 0.33, p = .003) as well for patients with 2
or more prior episodes (d = 0.39, p = .008). By contrast, in CBT, the alliance was
related to symptom change for patients with 0-1 prior episodes (d = 0.79, p < .001)
but not for those with 2 or more prior episodes (d = 0.06, p = .72). These findings
suggest a complex interaction between patient features and common vs. specific
therapy processes. In CBT, the alliance relates to change for patients with less
recurrent depression whereas other CBT-specific processes may account for change
for patients with more recurrent depression.
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INTRODUCTION
The therapeutic alliance, broadly understood to capture the bond between a
patient and a therapist as well as the agreement in the goals and tasks of therapy, is
widely believed to be a robust predictor of outcomes in psychotherapy. For example,
reviewing the literature on the alliance, Del Re, Horvath, Flückiger, Symonds, and
Wampold (2012) asserted that:
“the alliance and outcome have shown a remarkably robust association …
across different moderating variables such as measures of the alliance,
measures of outcomes (primary symptom measure and non-targeted
measures), rating perspectives, type of treatment (e.g., evidence-based,
manualized, focused on specific ingredients), and context in which treatment
was delivered.” (p. 643)
Indeed, the alliance-outcome correlation has been reported across various
patient populations and treatments (Horvath, Del Re, Flückiger, & Symonds, 2011).
However, there have been few primary analyses of the moderation of this
association, and even fewer analyses that have focused on patient characteristics as
potential moderators (De Bolle, Johnson, & De Fruyt, 2010; Falkenström, Granström,
& Holmqvist, 2013; Lorenzo-Luaces, DeRubeis, & Webb, 2014). Thus, whether the
alliance is an equally important predictor of outcomes for all patients and whether it
is an equally important predictor of outcomes across psychotherapies are still key
questions in alliance research (Barber, 2009). Moreover, the answers to these
questions may not be independent. In other words, it is possible that the effect of
the alliance on outcome is contingent on the interaction between the type of patient
undergoing treatment and the type of treatment that is being delivered. In one of
the few studies examining patient-level moderators of the alliance-outcome
correlation, Lorenzo-Luaces et al. (2014) reported that the alliance-outcome
correlation in cognitive therapy (CT) for depression was moderated by the number of
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prior episodes patients reported at baseline. The aim of this report is to replicate
these findings and extend them to psychodynamic psychotherapy.
Depressive recurrence
Lorenzo-Luaces et al. (2014) reported that for patients with fewer than three
prior episodes of depression, the alliance-outcome correlation was larger in
magnitude (r = 0.52) than what is commonly reported in the literature (r = 0.28;
see Horvath et al., 2011). By contrast, for patients with three or more prior
depressive episodes, the working alliance did not predict outcome (r = -0.02).
Drawing on prior work on recurrent depression these authors hypothesized that, for
patients with a highly recurrent course, depression had become more autonomous,
likely triggered by internal processes such as rumination or cognitive reactivity (Ma &
Teasdale, 2004; Monroe & Harkness, 2005; Wakefield & Schmitz, 2013). Individuals
with more recurrent courses are more likely to report depressive episodes that come
“out of the blue” (Ma & Teasdale, 2004). By contrast, patients with less recurrent
courses experience depressive episodes that are more closely linked to life stressors
(Monroe & Harkness, 2005). For these patients, agreement on the goals and tasks of
CT, which are often focused on concrete changes in behavior and thinking, may be
sufficient to engender changes in life circumstances and depressed mood. Adding
support to this hypothesis, Sasso et al. (2014) found that, in the same sample
investigated by Lorenzo-Luaces et al., therapists’ use of behavioral homework was
predictive of symptom change for less recurrent depression. It may be that concrete
behavioral changes, agreed on with the therapist, are sufficient to produce
substantial symptom change in less recurrent depression. An alternative account of
symptom change in less recurrent depression is that these patients may be better
able to benefit from nonspecific influences such as a positive bond with a caring
therapist.
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Patients with a more recurrent course depression may have, or may develop
during their clinical course, a greater vulnerability to depression that needs to be
addressed in order for treatment to be efficacious. For these patients, agreement on
the goals and tasks of CT, which are focused on concrete changes in behavior and
modification of negative automatic thoughts, may not be sufficient to engender
symptom change. Adding support to this hypothesis, Sasso et al. (2014) found that,
in the same sample investigated by Lorenzo-Luaces et al. (2014), therapists’ greater
use of cognitive methods (vs. behavioral homework) was predictive of symptom
change for clients with more recurrent courses of depression. Keefe et al. (2016)
found evidence that the specific use of interventions targeted at identifying,
assessing, and challenging patients’ core beliefs was specifically efficacious for
patients with more recurrent depression. Taken together, these findings are
consistent with the notion that CBT for patients with a more recurrent course of
depression needs to address underlying vulnerability factors, perhaps pertaining to
underlying core beliefs or schemas, in order to produce symptom change. This is
consistent with Ma and Teasdale’s (2004) proposition of “escalating cycles of
ruminative cognitive–affective processing” (p. 31) in more recurrent depressions.
Mindfulness-based CT (MBCT) was developed with the intent of interrupting these
processes and MBCT appears to be particularly superior to treatment as usual only
among patients with more recurrent forms of depression (Piet & Hougaard, 2011).
Taken together, findings from these studies suggest that the number of prior
episodes is a moderator of treatment outcomes as well as of process-outcome
relationships in cognitive-behavioral therapies (CBTs). Thus, the number of prior
episodes is an important variable to consider in the context of research on
treatments for depression.
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The alliance across psychotherapies
Meta-analytic reviews suggest that the magnitude of the alliance-outcome
correlation does not differ substantially between different therapeutic modalities
(Horvath et al., 2011). These findings could be taken to support the notion that the
therapeutic alliance is a common factor contributing to treatment outcomes in
different psychotherapies. However, these findings are not consistent with the fact
that schools of therapy emphasize the alliance to different degrees. For example, in
CBTs a positive therapeutic alliance is generally regarded as a necessary condition
for the implementation of cognitive-behavioral interventions, which are in turn
assumed to drive therapeutic change (Beck, 2011). In psychodynamic
psychotherapies, however, the alliance is more than a prerequisite in that
interventions often rely on the therapeutic relationship as a model. For example, the
therapist might focus on the relationship as a new and secure environment in which
the patient is invited to experience and talk about emotions that had previously been
avoided. Alternatively, the transference aspects of the relationship may be used to
improve insight into maladaptive expectations with regards to interpersonal
relationships (de Jonghe et al., 2013). Therapies might also be expected to differ in
regard to the role of the alliance because a component of the alliance is agreement
on task and goals, and therapies differ on their stated goals, as well as on the tasks
that are used.
Consistent with the differential roles of the therapeutic alliance, several
research groups have reported that treatments moderates the strength of the
association between the alliance and outcome. In a study of patients with chronic
depression, Arnow et al. (2013) found that the alliance was a significantly stronger
predictor of outcomes in cognitive behavioral analysis systems of psychotherapy
(CBASP) than it was in a supportive therapy. The authors hypothesized that the
difference was accounted for by CBASP’s greater emphasis on tasks and goals, a
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component of the alliance that may be more strongly related to outcomes than the
affective bond (see Rector, Zuroff, & Segal, 1999; Webb et al., 2011). Similarly,
Bedics, Atkins, Harned, and Linenhan (2015) reported that, in dialectical behavioral
therapy (DBT), the therapeutic alliance was associated with decreases in selfinjurious behavior, whereas this relation was not observed in non-behavioral
community treatment. Recently, Snippe et al. (2015) reported that the alliance
predicted symptom change in CBT for depression, but not in MBCT. Taken together,
these tests of moderation suggest a different role for the alliance across therapy
modalities (see also Strunk et al., 2010; Zilcha-Mano, Roose, Barber, & Rutherford,
2015), possibly varying according to how directive or task-oriented therapy is.
Objectives
In a new sample of patients with a major depressive episode (Driessen et al.,
2013), we aimed to replicate the finding of an interaction between number of prior
episodes and the alliance in CBT (Lorenzo-Luaces et al., 2014a). Moreover, we
attempt to extended the test of this interaction to psychodynamic therapy.
Replication attempts are extremely rare in psychology (Makel, Plucker, & Hegarty,
2012), and the rate of unsuccessful replications has spurred a crisis of confidence in
the findings derived from psychological studies (Open Science Collaboration, 2015).
Thus, our findings should make a substantial contribution to the field. The
exploration of patient characteristics and treatment as moderators of the allianceoutcome correlation is of special importance for treatment research. If the alliance is
only a predictor of outcomes in some patients but not in others, this could help
explain why in some studies the alliance predicts outcomes when accounting for prior
symptom change (Falkenström, Granström, & Holmqvist, 2014) but in others it does
not (Hendriksen, Peen, Van, Barber, & Dekker, 2014). Moreover, exploring the
intersection of patient characteristics, common factors, and specific therapeutic
factors can inform the personalized delivery of psychotherapeutic interventions
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(Beutler, Forrester, Gallagher-Thompson, Thompson, & Tomlins, 2012; Beutler &
Martin, 2001).
METHODS
Design. This paper draws upon data from a randomized clinical trial (RCT)
comparing CBT and short-term psychodynamic supportive psychotherapy (SPSP) for
patients with depression (N = 341; 164 in CBT and 177 in SPSP). This intervention
study was registered as ISRCTN31263312 with Current Controlled Trials
(http://www.controlled-trials.com). The study design and the study protocol were
approved by the Dutch Union of Medical-Ethic Trial Committees for mental health
organizations (Driessen et al., 2007).
Participants. Participants were referred by their general practitioner to one
of three psychiatric outpatient clinics in Amsterdam, The Netherlands. Inclusion
criteria were: 1) presence of a major depressive episode according to the MINIInternational Neuropsychiatric Interview – Plus DSM-IV criteria (Sheehan et al.,
1998); 2) Hamilton Rating Scale for Depression (HRSD; Hamilton, 1960) scores ≥
14; 3) age between 18 and 65 years; 4) written informed consent after description
of the study. Exclusion criteria and other design features have been described
elsewhere (Driessen et al., 2007; Driessen et al., 2013). Briefly, participants were
excluded if they were experiencing psychotic or manic symptoms, severe suicidality,
problematic substance use in the preceding 6 months, or if they were pregnant or
unable to attend the study assessments, or if they were using medications that
might influence mental functions. In this trial, the therapeutic alliance was assessed
at week 5. By this point, 59 patients had dropped out of the trial, 36 in CBT and 23
in SPSP (p =0.15, Fisher’s exact test). This report is focused on the remaining 282
patients (82.6% of the sample; 141 in CBT, 141 in SPSP).
Interventions. Both therapies consisted of 16 individual sessions in the
course of 22 weeks and were conducted according to published treatment manuals
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(de Jonghe, 2005; Molenaar, Don, van den Bout, Sterk, & Dekker, 2009). CBT was
based on the principles described by Beck (1976) and included behavioral activation
and cognitive restructuring according to a session-by-session protocol with
homework assignments. SPSP involved an open patient-therapist dialogue in which
supportive and insight-facilitating techniques are used (de Jonghe et al., 2013). Its
core technique is adequate psychoanalytic support. The therapist aims to address the
emotional background of depression by discussing current relationships, internalized
past relationships, and interpersonal patterns (de Jonghe et al., 2013).
Psychotherapists in both conditions were trained psychiatrists or psychologists.
Therapy sessions were not rated for adherence; manual fidelity was checked by
means of bi-weekly supervision sessions, chaired by a study supervisor, in which
audio-taped material was discussed.
Severely depressed (HRDS>24) patients at baseline, as well as moderately
depressed patients at baseline who developed severe symptoms during treatment
(HRDS>24), were offered adjunctive antidepressant medication. Medications were
administrated by a psychiatrist (not the patient’s therapist) according to a protocol
starting with extended-release venlafaxine 75 mg/day that could be raised to a
maximum of 225 mg/day. In cases of intolerance or complete nonresponse, patients
were switched to either citalopram or nortriptyline. Pharmacotherapy consults
addressed symptom evaluation, side-effects and adherence. The number of patients
starting pharmacotherapy at baseline or during psychotherapy did not differ
significantly between the treatment conditions (see Driessen et al., 2013).
Measures
Depression severity. We used continuous scores on the HRSD, a 17-item
observer-rated measure of depressive symptoms, as the primary outcome measure.
The HRSD was assessed at baseline, weeks 5, and 10, and at the end of treatment
(i.e., week 22). HRSD assessors were trained master-level clinical psychology
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students, not blind to treatment condition, who assessed the HRSD according to the
Dutch scoring manual (de Jonghe, 1994). The average intraclass correlation
coefficient over 46 audiotaped assessments scored by multiple assessors was .97. Of
the 282 patients who remained in the trial through week 5, 247 (88%) provided an
HRSD score at week 5.
Therapeutic alliance. The alliance was assessed with the Helping Alliance
Questionnaire (HAq-I; Luborsky, Crits-Christoph, Alexander, Margolis, & Cohen,
1983), an 11-item self-report questionnaire measuring the perceived helpfulness of
the therapy as well as the quality of the cooperative or working alliance. Items are
rated on a 7-point Likert scale, with higher scores indicating a stronger therapeutic
alliance. Because the items measuring the perceived helpfulness of therapy are
contaminated by prior symptom change, only items 6 – 10, which tap the
collaborative aspect of the relationship, were analyzed (hereafter we refer to this as
the HAq-Ic; de Weert-Van Oene, de Jong, Jörg, & Schrijvers, 1999; Hendriksen et
al., 2010). Of the patients who remained in the trial by week 5, 197 (70%)
completed the HAq-Ic. The internal consistency of the subscale was 0.88.
Depressive recurrences. History of prior depression was ascertained from
patient’s self-report as part of an unstructured clinical interview with a master’s level
clinician. Patients indicated whether they had 0, 1, or 2 or more prior depressive
episodes.
Analytic Plan
Missing HAQ-Ic and HRSD data were handled using non-parametric
imputation via random forests with the missForest package in R (Stekhoven &
Bühlmann, 2012). Covariates used for the imputations were the HAq-Ic and HRSD
scores, treatment condition, prior episodes, and the other baseline variables
displayed in Table 3.1. All descriptive and inferential analyses were conducted in IBM
SPSS v.22. Data were centered according to Kraemer and Blasey’s (2004)
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recommendations. We used hierarchical linear models (HLMs) to predict change over
time on the HRSD, the primary study outcome. In all analyses, we controlled for
early symptom change (baseline to week 5), whether the patients were on
medications, and the medication by treatment interaction.
To control for the nesting of data within therapists, a variable representing
therapists was specified as a random effect. We controlled for early symptom
change, as opposed to including baseline and week 5 HRSD scores, because adding
early change to the statistical models increased fit more than did adding baseline and
week 5 scores. Additionally, controlling for baseline HRSD scores would prohibit
controlling for medication status because these variables are non-independent (i.e.,
baseline HRSD determined whether patients received medication or not). Controlling
for baseline severity and week 5 severity instead of early change does not change
the pattern of results.
We first estimated the overall effect of the alliance on outcomes by modeling
change on the HRSD as a function of the alliance and the alliance by time interaction.
Then, to probe whether the alliance interacted with the number of prior episodes, we
explored the interaction of time, the alliance, and prior episodes, with all lower-order
interactions and the statistical controls (i.e., early symptom change, medications,
medications X treatment, and their interactions with time). We also present the tests
of the alliance X episode X time interaction according to treatment condition. To
probe whether the relation of prior episodes and alliance in predicting outcomes
varied as a function of treatment condition, we analyzed the interaction of alliance X
prior episodes X treatment X time, with the lower-order interactions and statistical
controls. We present effect size estimates in accordance with the framework of
Feingold (2013).
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RESULTS
An HAq-Ic was available for a higher proportion of clients with 2+ prior
episodes (76%), compared to those with 0-1 prior episodes (64%; p = 0.038,
Fisher’s exact test [FET]). A higher proportion of HAq-Ics were available for clients in
the SPSP condition (74%) than for clients in the CBT condition (65%), but this
difference was not significant (p = 0.12, FET). There was a tendency for clients in
the medication condition (63%) to be less likely to provide an HAq-Ic, relative to
those not on medication (74%; p = 0.06, FET). There were no differences between
participants who provided a HAq-I and those who did not on any of the other
variables listed in Table 3.1 (all ps > 0.16).
On average, clients rated their alliance with their therapist as high (M = 5.24,
SD = 1.01, where the possible range was 1-7; see Table 3.1). Alliance scores were
non-significantly higher in CBT condition (M = 5.32, SD = 0.90) relative to the SPSP
condition (M = 5.15, SD = 1.11; t(280) = 1.37, p = 0.17). Alliance scores were not
correlated with the number of prior episodes reported (r = 0.004, p = 0.95) and the
test of the interaction of treatment condition with the number of prior episodes in
predicting the HAq-Ic scores was not significant (B = 0.06, SE = 0.14, x2 = 0.23, p =
0.63). These results indicate that, as expected, the levels of alliance did not vary as
a function of the number of prior episodes, treatment condition, or their interaction.
The model predicting change on the HRSD yielded a significant relation of the
alliance to outcome (B = -1.99, SE = 0.38, t(715.8) = -5.18, p < 0.001; d = 0.37).
The interaction between prior episodes and the alliance was not significant in the
SPSP condition (B = 0.20, SE = 0.58, t(367.38) = 0.36, p = 0.72). However, in the
CBT condition, there was a statistically significant interaction between prior episodes
and the alliance in predicting outcomes (B = 1.88, SE = 0.66, t(349.50) = 2.83, p =
0.005). Although the interaction between time, the alliance, prior episodes and
treatment did not reach statistical significance (p = 0.059), examination of the effect
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sizes associated with changes in the alliance (see Figure 3.1) shows that the alliance
was a predictor of outcomes in SPSP for participants with 0 – 1 prior episodes (B = 2.09, SE = 0.69, t(172.69) = -3.00, p = 0.003, d = 0.33) as well as for those with
2+ episodes (B = -1.79, SE = 0.66, t(191.66) = -2.70, p = 0.008, d = 0.39). By
contrast, in CBT the alliance was a strong predictor of outcomes for those with 0 – 1
prior episodes (B = -4.24, SE = 0.93, t(179.96) = -4.56, p < 0.001, d = 0.79) but
not for those with 2+ episodes (B = -0.30, SE = 0.86, t(166.33) = -0.36, p = 0.72,
d = 0.06).
DISCUSSION
We aimed to replicate and extend the findings of Lorenzo-Luaces et al. (2014)
that, in CBT, the association between the therapeutic alliance and subsequent
change in depression varied as a function of the number of prior depressive episodes
clients reported at baseline. The present findings suggest that whereas in
psychodynamic psychotherapy the therapeutic alliance is a robust predictor of
outcomes, in CBT the effect of the alliance on outcomes is contingent on a client
characteristic indexed by the number of previous depressive episodes. This finding
contributes to the small number of studies on the moderation of process-outcome
relations by suggesting that process-outcome correlations can vary as a function of
the interaction of common and specific therapeutic processes and identifiable client
features (Beutler & Harwood, 2002; Beutler & Martin, 2001; DeRubeis, Gelfand,
German, Fournier, & Forand, 2013).
Limitations and strengths
A number of limitations, some of which are the consequences of analyzing
data collected in a naturalistic context, must be considered when interpreting the
findings from the present analyses (see Driessen et al., 2007; 2013) for discussions
of the limitations of the parent RCT). Some of the most notable limitations of the trial
from which these data were analyzed were the fact that HRSD raters were not
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blinded to treatment conditions as well as the fact that treatment adherence was not
formally addressed. We examined moderation of the alliance-outcome relation only
in the subset of clients who remained in treatment for at least five weeks. Although
we imputed missing data for clients who were in treatment at week 5 but did not
complete an alliance assessment, we chose not to impute data for those who
dropped out early, as this is a systematic reason for missingness. In this way, the
generalizability of our results is limited. We note, however, that even considering
only the clients with complete data, the sample size in this study is larger than more
than 90% of the studies included in the most recent alliance-outcome meta-analysis
(Horvath et al., 2011).
Only week 5 assessments of the alliance were available in this trial. Earlier
assessments are preferable because they are less likely to be contaminated by
symptom change. We controlled for prior change statistically, but we cannot rule it
out as a source of contamination. Moreover, the number of prior episodes in this trial
was assessed as either zero vs. one vs. two or more. This did not allow us to
estimate the alliance-outcome correlation for the subset of clients who would have
reported an even higher number of prior episodes.
Although the four-way interaction between time, the alliance, prior episodes,
and the treatment condition did not cross the traditional threshold for statistical
significance, the interaction between time, the alliance, and prior episodes was
significant in the CBT condition, in the direction and magnitude reported previously
(Lorenzo-Luaces et al., 2014). The current report thus is noteworthy, especially
given the so-called replication crisis in psychology (Open Science Collaboration,
2015) and the fact that interactions are especially difficult to replicate (Benassi &
Belli, 1989). It is also important to observe that this replication effort occurred in a
different cultural context, with different measures of both the alliance and of
depressive symptoms. This suggests that the original findings were unlikely to have
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resulted from artifacts of the measures used in that study, but that instead they
reflect true relations between these constructs.
The alliance in different therapies
The therapeutic alliance is not a mechanism within the client that mediates
symptom change, nor is it a set of therapist behaviors. Thus, an account of symptom
change that invokes the alliance must also consider the behavior of therapists as well
as the psychological targets that such behavior is presumed to influence. Change in
overly negative thinking appears to be a general mechanism of change in
psychotherapies for depression (Lorenzo-Luaces, German, & DeRubeis, 2015). These
negative thinking patterns are more rigidly held and more easily activated in
recurrent depression. It is possible that they need to be addressed directly for
symptom change to occur (Ma & Teasdale, 2004; Monroe & Harkness, 2005).
Although the goal of changing negative thinking patterns is common to
psychodynamic and cognitive therapies, the ways in which such changes are
targeted differs markedly between the therapies. In CBTs, agreement on the goals
and tasks of therapy, which involve cognitive and behavioral work aimed at fostering
cognitive change, has been shown to predict subsequent symptom improvement
(Rector et al., 1999; Webb et al., 2011). In short-term psychodynamic therapy, the
development of a secure therapeutic relationship is seen as a vital process thought
to facilitate the development of insights that reveal maladaptive patterns of
expectations in the context of interpersonal relationships. Moreover, the client is
encouraged to experience affect that has been avoided. Given that a core technique
in SPSP is the provision of support, alliance building is technique and vice versa.
Thus, the therapeutic alliance ratings may represent somewhat different constructs
across psychotherapies in that they relate to the different roles that the alliance is
assigned, and the different ways in which change is promoted. Findings from studies
in which the alliance is measured either in placebo or pharmacotherapy conditions
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also supports the view that ratings of the therapeutic alliance may represent
different constructs across treatments (Barber et al., 2014; Strunk et al., 2010;
Zilcha-Mano et al., 2015).
Less recurrent depression. Patients with less recurrent depression may
have less of a latent vulnerability to depressive episodes (Monroe & Harkness, 2005).
In these patients, the alliance in CBT and SPSP appears to lead to symptom change.
Life stressors often trigger depression in these individuals. One possibility is that
they benefit sufficiently from the provision of non-specific support on part of the
therapist as a way of remoralizing the patient or helping him or her to overcome
specific problems. Areán et al. (2015) conjectured that the provision of specific
psychotherapeutic techniques meant to address psychopathology may not be
necessary for all patients and that many individuals could experience improvement in
functioning with the provision of assistance dealing with current life stresses. In
other words, for some patients it may not so much matter whether therapists
attempt to foster symptom change by engaging in specific techniques like
encouraging behavioral change, cognitive change, providing support, or exploring
interpersonal patterns. Rather, engaging in any of these behaviors as a way of
helping to resolve interpersonal stressors and countering patients’ depressed mood
may drive symptom change. For these patients, perhaps it is the agreement between
them and their therapist in a course of action, irrespective of what is being agreed
about, that promotes symptom change. It is worth observing that the effects of the
alliance for those with less recurrent courses of depression appeared stronger in CBT
than in SPSP. One possibility is that it may more conducive to symptom change for
patients and therapists to focus on concrete (Keefe et al., 2016), especially
behavioral (Sasso et al., 2014), changes, possibly because they are easier for both
the patient and the therapist to carry out. This hypothesis should be explored in
future work. There already are treatment approaches that rely on behavioral
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strategies as first steps in the treatment of depression only to be succeeded by other
therapeutic strategies if the behavioral methods do not produce symptom change
(Alexopoulos & Areán, 2014).
More recurrent depression. Individuals with more recurrent courses of
depression often experience depressive episodes as if they came “out of the blue”
(Ma & Teasdale, 2004). Evidence suggests that individuals with more recurrent
depression, as those who are considered at high risk for depression, may actually be
experiencing depression in response to stressors that are very minor, including even
so-called “daily hassles” (Monroe & Harkness, 2005; Sher, 2004). These minor
stressors, in vulnerable individuals, may be enough to trigger the cognitive-affective
networks associated with self-perpetuating depressed mood. Individuals with a
recurrent history of depression have long histories of experiencing these shifts in
mood and may therefore may not experience them as being connected to cognitive
or meta-cognitive patterns. For these individuals, agreement with their therapists in
the goals and tasks of CBT did not appear to lead to symptom change. It is
important to observe that individuals with more recurrent depression did not
experience worse outcomes in CBT than in SPSP, but rather the outcomes were not
linked to the level of agreement in the goals of CBT. It is possible that agreement in
the concrete goals and tasks of therapy, at least as they have been discussed early
in treatment, (i.e., to promote behavioral change and change on negative automatic
thoughts) does not promote symptom change. Cognitive work at the deeper level of
schemas (Keefe et al., 2016) that is meant to address the underlying vulnerability to
depression may be required to promote symptom change. In other words, it may not
be the work on automatic thoughts per se, a concrete goal of CBT, that leads to
symptom change, but rather it is the identification of patterns of maladaptive
thoughts and their underlying schemas that promote symptom change. Alternatively,
other processes that were not explicit goals of CBT may also account for symptom
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change in CBT for recurrent depression. For example, a standard course of CBT may
increase mindfulness (Manicavasagar, Perich, & Parker, 2011), or it may promote
affective shifts (Hayes et al., 2007), both of which have been hypothesized to reduce
vulnerability to depression.
The finding of this study as well of Lorenzo-Luaces et al. (2014), that
measures of the therapeutic alliance did not predict outcomes for clients with more
recurrent depression in CBT, should not be taken to mean that the quality of the
alliance is unimportant for these clients. High scores on measures of the therapeutic
alliance are typical in most studies of the alliance (Barber, 2009). It is possible that if
the lower range of alliance scores were sampled, a relationship of the alliance and
outcomes would be evident for clients with more recurrent depression in CBT. That
is, even if other therapeutic elements of CBT are promoting symptom change in
clients with more recurrent depression, it is possible that these require the presence
of an at least “good enough” therapeutic alliance.
The finding of an interaction between prior episodes and the alliance in CBT
raises the question of why such an interaction would not be found in psychodynamic
therapy. In psychodynamic therapies, the alliance is hypothesized to be key to
structural change for all clients. Inasmuch as therapist interventions are performed
using the therapeutic alliance, the alliance may represent a process of
psychodynamic therapies that is active across all clients. Our findings can be taken
to lend credence to this view that the alliance is instrumental in psychodynamic
therapy. It may be that the SPSP goal to analyze maladaptive depressogenic
patterns that occur throughout the life course (de Jonghe et al., 2013), which is done
using the therapeutic alliance, produces symptom change because it reveals the
cognitive-affective schemas that are activated in the context of depression.
Alternatively, the exploration of affect, which is a stated goal of SPSP but not of CBT,
may also promote symptom change (Hayes et al., 2007).
59

Conclusions
The current findings suggest that psychodynamic and cognitive-behavioral
therapists achieve symptom change via different means with different clients, rather
than through the common pathway suggested by proponents of the common factors
of psychotherapy. Beutler and colleagues have argued for a move away from
theories of common vs. specific factors of therapy and towards personalizing
treatments by applying therapeutic procedures that match clients’ presenting style
(Beutler et al., 2012; Beutler & Harwood, 2002; Beutler & Martin, 2001). Our results
suggest that the number of prior depressive episodes clients report before initiating
treatment is an important variable to consider when tailoring treatments to
individuals. Within psychodynamic therapies, the alliance, in conjunction with other
processes engaged in treatment, leads to positive outcomes irrespective of the
number of prior episodes. By contrast, in CBT, it would appear that the processes
captured by measures of the therapeutic alliances are only predictive of outcomes for
clients with less recurrent forms of depression. Other CBT processes, for example, a
greater focus on cognitive change, may better account for symptom change in clients
with more recurrent depression.
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Table 3.1 Baseline characteristics of 282 clients assigned to cognitive-behavioral
therapy (CBT) or short-term psychodynamic supportive psychotherapy (SPSP) for
depression
M
SD
% miss.
HAq-Ic
Baseline HRSD
Early HRSD change
HRSD week 5
HRSD week 10
HRSD week 22
Female
Married
Treatment allocation
CBT
SPSP
Medication
Prior episodes
0 - 1 episodes
2+ episodes
Duration of depression

5.24
23.38
3.59
19.79

1.18
5.38
5.85
7.39

18.30
15.09

8.12
8.74

0
12
12
16
19

%

N

% miss.

68

193

25

70

0
0
0

50
50
37

141
141
105

50
50

141
141

30

0
0

4

< 6 months
6-12 months
12 – 24 months
> 24 months

26
23
14

74
66
38

35

93

Age

1
19-29

30-39
40-49
50-64
Female
Married
Employment status
Employed
Student
Unemployed or other
Educational attainment
Low
Intermediate

26
23
14
33

70
80
86
46

68
25

193
70

39
4
57

111
10
161

0
0
0

1

59
130
90
High
32
Note. HAq-Ic- Helping Alliance Questionnaire, Cooperation subscale, Alliance
subscale. % miss = percentage missing data at baseline. HRSD – Hamilton Rating
Scale for Depression. Early HRSD change – change from week 1 to week 5.
21
46
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Figure 3.1 Association between the alliance and symptom change by treatments and
prior episodes
Note: Prediction of change on the Hamilton Rating Scale for Depression from the
mean score on items 6-10 on the Helping Alliance Questionnaire HAq-Ic, controlling
for therapist effects, medication status, and early symptom change. The dashed line
represents the effect of HAq-Ic on symptom change for the whole sample, controlling
for early change, treatment condition, medication status, and the interaction of
treatment condition and medication status. CBT = cognitive behavioral therapy,
SPSP = short-term psychodynamic supportive psychotherapy
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CHAPTER 4: GENERAL DISCUSSION
The studies presented as a part of the dissertation explored ways in which the
heterogeneous nature of depression moderates treatment effects and the effects of
treatment processes on outcomes. Taken together, the findings suggest that the
efficacy of evidence-based psychotherapies and the effects of specific psychotherapy
processes are limited to specific, potentially identifiable, subsets of clients. Although
it might seem obvious that heterogeneity should be considered when interpreting
treatment effects and psychotherapy process research findings, there is very little
work that specifically addresses this issue.
The first study explored differential treatment outcomes in the context of a
trial that reported negligible differences between a high-intensity treatment regime
starting with CBT, a lower-intensity stepped care condition starting with BT, and
treatment as usual (TAU). A closer examination of the data revealed that the
treatments were equally efficacious for most of the sample, but that CBT was
superior to BT and TAU in the subset of clients who were expected to have a poorer
prognosis. The second study explored the variability of the effects of the working
alliance, a psychotherapy construct traditionally associated with nonspecific or
common psychotherapy effects that has been reported to have a moderate and
consistent relation to outcomes. In a sample of clients receiving CT for depression,
for clients with less recurrent depression the alliance was a stronger predictor of
outcomes than is generally reported in the research literature. By contrast, for clients
with more recurrent depression, the alliance did not predict outcomes. In the third
study, these findings were replicated in the CBT condition of a randomized controlled
trial (RCT). However, the findings did not generalize to the short-term psychoanalytic
supportive psychotherapy (SPSP) condition in the RCT, suggesting that this pattern
may be specific to CBT.
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In the study of psychotherapy effectiveness, equivalent outcomes between
different forms of therapy have often been reported, leading to an assumption of
equipotency of psychotherapies dubbed the “Dodo bird verdict” (Luborsky, Singer, &
Luborsky, 1975; Messer & Wampold, 2002; Rosenzweig, 1936). Some have gone so
far as to argue that TAU psychotherapy and manualized evidence-based treatments
produce equivalent outcomes (Flückiger, Del Re, Munder, Heer, & Wampold, 2014;
Spielmans et al., 2013). One account that has been given for why all treatments
should or would be equally efficacious is the common factors theory of symptom
change (Laska et al., 2014). The proponents of common factors theory assert that all
psychotherapeutic interventions delivered with the intent of being efficacious (e.g.,
TAU, CBT) are equally effective because they all include:
“factors that are necessary and sufficient for change: (a) an emotionally
charged bond between the therapist and patient, (b) a confiding healing
setting in which therapy takes place, (c) a therapist who provides a
psychologically derived and culturally embedded explanation for emotional
distress, (d) an explanation that is adaptive … and is accepted by the patient,
and (e) a set of procedures or rituals engaged by the patient and therapist
that leads the patient to enact something that is positive, helpful, or
adaptive.” (Laska et al., 2014; p. 469)
An alternative account to the Dodo and the common factors theory is that,
although many treatments might be equally effective for many clinical conditions,
some are better suited for dealing with specific problems (DeRubeis, Brotman, &
Gibbons, 2005). Evidence has recently accumulated to support this position (Bell,
Marcus, & Goodlad, 2013; Forman et al., 2012; Marcus, O'Connell, Norris, &
Sawaqdeh, 2014; Poulsen et al., 2014; Tolin, 2010, 2014). For example, Marcus et
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al. found CBT to be superior to other treatments for anxiety and eating disorders, but
not for depression. These authors stated that their findings:
“are consistent with Chambless’ (2002) suggestion that there may be higher
levels of treatment equivalence for some disorders such as depression and
greater treatment differences for disorders like panic disorder. In other words,
there may be Dodo disorders and non-Dodo disorders. Similarly, Westen,
Novotny, and Thompson-Brenner (2004) noted that short-term targeted
treatments may be most effective for treating disorders characterized by
specific discrete symptoms (e.g., panic disorder), but may be less effective
for treating “generalized affect states” (p. 655) or more characterological
conditions such as depression or GAD.” (p. 527)
The findings from study 1 suggest that –even within “Dodo disorders”— there
is variability in the extent to which treatment differences will be evident. For clients
with a favorable prognosis, treatment differences may be small or non-existent. In
this context, it is not too surprising that treatment researchers are frequently
disappointed by the size of the effect of interventions. Although meta-analytic
reviews, even those conducted by researchers who are not proponents of evidencebased practices (EBPs), have yielded estimates suggesting that EBPs are superior to
TAU (Flückiger et al., 2014; Spielmans et al., 2013; Stewart & Chambless, 2009;
Wampold et al., 2011; Weisz, Jensen-Doss, & Hawley, 2006), these findings have
often been dismissed on the grounds that the differences do not appear to be large.
To the extent that these studies have been conducted in client samples with a
favorable prognosis, it is to be expected that differences between active treatments
and controls, as well as between treatments that might differ in their potency, will be
small. In depression, most comparisons between treatments have been conducted in
samples of clients with mild to moderate depression (Barth et al., 2013), precisely
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the types of clients we would expect to benefit from any intervention (Barbui,
Cipriani, Patel, Ayuso-Mateos, & van Ommeren, 2011; Bower et al., 2013; Driessen,
Cuijpers, Hollon, & Dekker, 2010; Fournier et al., 2010; Khan, Leventhal, Khan, &
Brown, 2002; Kirsch et al., 2008). Subgroup analyses by severity have shown some
differences between psychotherapies but these findings have been inconsistent
(Dimidjian et al., 2006; Driessen et al., 2014; Elkin et al., 1995; Luty et al., 2007).
Moreover, severity is only one variable that indexes prognosis. In one study that
looked at the interaction of variables, Driessen et al. (2014) reported that CBT was
slightly more effective than SPSP for clients with severe depression (d = 0.36)
especially if it was not chronic (d = 0.86) whereas a small advantage for SPSP was
detected in severe and chronic MDD (d = 0.31). These findings suggest that the
relationship between expected prognosis and treatment outcomes may be curvilinear
or otherwise more complex than we have presented.
The fact that for many clients any treatment will lead to symptom change
should not be dismissed as a statistical artifact or as a reason to focus only on those
clients who provide evidence of differences between treatments. An understanding of
the lack of differences between active treatments and controls or TAU, or between
treatments, has important implications for the delivery of mental health care. Given
that for clients with a good prognosis there seem to be few appreciable differences
between treatments, average treatment outcomes cannot be the consideration taken
when giving treatment to these clients. Other variables, such as cost or ease of
dissemination, must be considered. For example, it has been argued that behavioral
activation (BA) should be considered a first-line treatment for depression given that
it may engender as much change, on average, as CBT, and it is expected by many to
be easier to disseminate than CBT. Although there are few published data that speak
to former assertion, and no data that address the latter conjecture, these questions
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are currently being explored in the United Kingdom (Rhodes et al., 2014).
Analogously, Alexopoulos and Arean (2014) have developed and tested a stepped
therapeutic approach that begins with behavioral activation and only adds other
components of CBT (e.g., cognitive restructuring, emotion regulation skills) if it is
deemed that they are needed. Although both of these studies represent notable
advances in research on psychotherapy, the underlying assumption in these
approaches is that individual therapist contact is required for therapeutic
improvement. However, as the findings of chapter 1 and the findings from metaanalytic reviews (Barbui et al., 2011; Bower et al., 2013; Driessen et al., 2010;
Fournier et al., 2010; Khan et al., 2002; Kirsch et al., 2008) suggest, clients with a
more favorable prognosis may not need high-intensity treatments requiring therapist
contact. As has been noted by others (Kazdin & Blase, 2011), self-help, mediabased, and technology-assisted interventions may all contribute to reducing the
burden of disease in clients with a better prognosis.
In addition to helping guide treatment selection, parsing out heterogeneity in
depression and other disorders might be required in order to uncover mechanisms of
treatment and of pathology. As shown in Chapters 2 and 3, processes that are
assumed to be part of causal chains in psychotherapy may operate differently across
client types, and even across the type of psychotherapy that is delivered. For
individuals with less recurrent depression, a positive working alliance irrespective of
therapy modality (Chapters 2 and 3), the use of behavioral homework (Sasso et al.,
2015), and clients’ self-reported behavioral changes (Lorenzo-Luaces, German, &
DeRubeis, 2014) appear to be associated with symptom change. In individuals with
more recurrent depression, cognitive change (Lorenzo-Luaces, German, & DeRubeis,
2014) and a positive working alliance in psychodynamic therapy (Chapter 3) are
associated with symptom change. These findings may be interpreted in light of
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theories of stress sensitization in depression which posit that prior depressive
episodes change individuals in ways that leave them at a higher risk of developing
subsequent depressive episodes (Monroe & Harkness, 2005).
One way in which depression may render individuals at higher risk for
subsequent depression is by strengthening cognitive-affective networks associated
with depressive states (Segal, Williams, Teasdale, & Gemar, 1996). Depression then,
in individuals with more recurrent trajectories, may result from the activation of
internal vulnerabilities with little or only minor stress, or even autonomously (Ma &
Teasdale, 2004; Monroe & Harkness, 2005). If this is so, recovery from depression
for individuals with more recurrent courses may require addressing the internal
factors (e.g., cognitive reactivity) that underlie the individual’s vulnerability to
depression. As suggested by the results of post-hoc analyses of the trial from which
the data in Chapter 2 were derived, addressing cognitive vulnerabilities may be one
way of fostering symptom change (Lorenzo-Luaces, German, & DeRubeis, 2015;
Sasso et al., 2015). In the analyses presented in Chapter 3, psychodynamic therapy
and CBT achieved similar levels of symptom change among clients with more
recurrent depression, and in dynamic therapy the alliance was related to symptom
change.
In a case description of a course of SPSP, de Jonghe et al. (2013) provided
information that is suggestive of processes that may account for symptom change in
recurrent depression with SPSP. In the first few sessions, the therapist provides
psycho-education and discusses day to day coping with symptoms but refrains from
giving further advice. Next, explanations for depression are explored and the
therapist emphasizes the relation of depression to circumstances (“there was a lot to
do … “But somehow I was not ‘there’ at work; it was as if I was constantly
somewhere else in my thoughts. I was criticized for that and it upset me a great
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deal.” [p. 618]). At first glance, emphasizing the relation between events and moods
might not seem highly applicable to clients with a more recurrent course. However,
the therapist complements this approach by saying: “Everybody’s life … is highly
determined by what happens and even more by the way events are perceived” (p.
618, emphasis added). As the therapy progresses, patterns from troubling and
depressogenic situations are extracted in a supportive-expressive manner (“The
therapist values her growing awareness of an interfering pattern or theme in her life
[“being overlooked”])” (p. 619) This is followed by a shift in focus to internal life and
it is revealed that “[the client] seldom speaks her mind from fear she might “give the
wrong answer. ‘I am always afraid they’ll think I am a stupid, fat girl’.” (p. 619). The
client and the therapist have jointly discovered that “the problem is not out there but
inside her” (p. 619). The subsequent stages of the treatment involve trying to
uncover the roots of depressive thinking and recognizing that they might be related
to early life experiences and hence are not facts that should be acted upon.
It is thus possible to conceptualize the SPSP treatment of recurrent
depression as providing a meaningful narrative for depression rather than accepting
that it has simply arisen out of the blue or with little provocation. It might be that it
does not so much matter whether the narrative is “accurate” but rather whether the
client is able to recognize depressive thinking when it is activated and counter it with
adaptive, opposite, beliefs and behaviors. It is of note that the therapist and the
client worked slowly and collaboratively through this explanation and it required the
use of supportive interventions that were not meant to challenge thoughts, especially
early on. Thus, a positive working relationship in which the client and the therapist
are able to construct a narrative for depression that involves depressogenic thinking
might explain symptom change in recurrent depression with SPSP. SPSP also entails
exploration of affect in the working relationship with the therapist and in that sense
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may produce cognitive change in a manner similar to what likely occurs in exposurebased CT treatments (Hayes et al., 2007).
A CBT approach towards promoting symptom change in recurrent depression
might have been in some sense more straightforward than the SPSP approach
described above. It may have begun by focusing on thoughts, somewhat reducing
the importance of a highly positive working alliance. Providing support for this view,
a recent dismantling trial suggested that the cognitive psychoeducational part of
mindfulness-based CT may, on average, account for its efficacy in recurrent
depression relative to the full MBCT package and to TAU (Williams et al., 2014). Note
that this is not meant to imply that a positive working alliance is not needed for
clients with recurrent depression undergoing CBT. That is an empirical question that
existing trials are ill-equipped to answer because most ratings of the therapeutic
alliance, whether by clients, therapists, or observers, suggest that good working
relationships characterize the great majority of client-therapist dyads. The most that
can be said is that, given the “good enough” levels of the working relationship that
appear to have been present in nearly all the dyads studies in Chapters 2 and 3, in
CBT the presence of an even better working relationship with a recurrently depressed
individual did not appear to be necessary for promoting substantial symptom change.
Individuals with less recurrent depression typically experience depressive
episodes that are triggered by life stress. It is possible that for many of these
individuals the process of change in psychotherapy may be better conceptualized as
one of remoralization and reengagement with positive and rewarding experiences
(Connor & Walton, 2011). In a similar vein, in a study that failed to find a significant
difference between problem-solving therapy (PST) and clinical management (CM) +
PST in a low-income, medically ill population, Areán et al. (2015) conjectured that
the resolution of health and psychosocial stressors from CM was enough to drive
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change in depression and increase self-efficacy and problem-solving skills. It may
have been the case that many of these clients did not have deficits in problemsolving skills, the pathology PST targets, but were struggling to adjust to their
environments. It should be an aim of future research to identify subgroups of clients
that may better helped by therapeutic techniques that focus more on helping clients
solve external problems than on helping to alleviate pathology.
One of the guiding assumptions of the research on common factors of
psychotherapy, like the therapeutic alliance, is that these factors account for
symptom change for all clients. At the statistical level, an assumption like this can be
evaluated by conducting a test of whether process-outcome correlations are
moderated by client features. Meta-analytic reviews have presented tests of whether
the strength of the magnitude of process-outcome correlations varies as a function of
the client samples in which studies are conducted. The results of these studies
suggest that the alliance-outcome correlation diminishes insofar as the study
samples contain individuals who are more educated (Sharf, Primavera, & Diener,
2010), have substance use disorders (Flückiger et al., 2013), or belong to racial and
ethnic minority groups (Flückiger et al., 2013). Because meta-analyses refer to
studies, and not to individual clients, more primary tests of moderation like the ones
conducted in Study 2 and 3 are needed.
Our findings suggest that the alliance is not a common factor either across
types of clients or across therapeutic modalities. These findings can be understood if
we consider that agreement on the goals and tasks of the therapy cannot be a
common factor because the goals and tasks of therapies differ. However, providing
explanations for processes of change that incorporate the alliance and therapyspecific variables can prove very challenging at a conceptual level and will probably
be difficult to detect statistically. Data-mining enterprises such as the ones
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conducted in Chapter 1 and 2 may reveal interesting relationships that have not
been theorized. The important issue will be to attempt to replicate and extend these
findings as in Chapter 3.
The findings of heterogeneity as affecting treatment effects and processoutcome correlations also have important implications for the classification of
depression. Insofar as there are cases of MDD that may be better understood as
demoralization, it may be that those individuals lack the pathologies traditionally
associated with MDD (e.g., maladaptive negative cognitive biases). As such, these
individuals may not be helped more by treatments that are meant to target the
pathologies in MDD (e.g., cognitive therapy) more than they would be helped by
TAU, brief, or low-intensity interventions. It should be the aim of future work to
differentiate between individuals who are more in need of active and specific
treatments vs. lower-intensity interventions and to uncover mechanisms of
pathology that can be linked to treatment effects.
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